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1. THE GLIAL CELLS 
 
Neurons and glia are the main groups of cells present in the nervous system. Neurons 
are excitable cells responsible for information processing and transmission. Glia, as the Greek 
name indicates, has been traditionally considered as the “glue” of the nervous system, 
providing structural and metabolic support to neurons and creating a proper environment for 
them. In the central nervous system (CNS), glia can be classified into three different types: 
astrocytes, which have different functions, including providing metabolic support to axons, 
recycling neurotransmitters from the synaptic cleft, buffering extracellular potassium 
concentration and forming the blood brain barrier; microglia, the resident immune cells in the 
brain, which engulf cellular debris and secrete both pro and anti-inflammatory molecules, and 
oligodendrocytes (OLs), which produce the myelin sheath around axons, providing protection 
and metabolic support to neurons and facilitating the saltatory conduction of axon potentials. 
  
The understanding of the role of glial cells in the CNS function has extraordinarily 
progressed during recent years, and the interest in their study has greatly increased. Glial cells 
are indispensable for correct neuronal development and functioning, being their ability to 
respond to changes in the cellular and extracellular environment crucial to the function of the 
nervous system. The presence of neurotransmitters, their transporters and receptors in glial 




Oligodendrocytes are the myelin forming cells in the vertebrate CNS. They were 
described by Pío del Río Hortega in 1921 as cells with small cell bodies filled with nuclei 
containing large amounts of chromatin and a tremendous complexity of cellular extensions 
without fibers but with cytoplasmic granules (del Río Hortega, 1921; Simons and Nave, 2015). 
Although the main role of OLs is the synthesis of myelin around CNS axons, there are also 
“perineural satellite oligodendrocytes” in close contact with neurons that regulate the 
microenvironment around them (Baumann and Pham-Dinh, 2001). Some other 
oligodendroglial cells are found in the vicinity of small vessels and are subclassified as 
“perivascular satellites” (Simons and Nave, 2015). Recently, Marques et al. (2016) have 




suggesting that, among them, mature OLs are region specific. Thus, OLs are a highly diverse 
and specialised cell population. 
 
Mature myelinating OLs are postmitotic cells that develop from glial precursors named 
oligodendrocyte precursor cells (OPCs) which express the platelet-derived growth factor 
receptor α (PDGFRα) and the proteoglycan NG2. Besides forming OLs during brain 
development, OPCs remain present in the adult CNS and constitute the main proliferating cell 
type (Dawson et al., 2003). OPCs express a wide variety of receptors and can respond to 
neuronal derived signals such us neurotransmitters, growth factors or cell adhesion ligands. 
  
Self-renewing neural stem cells (NSCs) in the developing brain produce multipotent, 
non-self-renewing neural progenitor cells (NPCs), which under specific signals begin to express 
oligodendrocyte transcription factor 2 (Olig2), triggering the first embryonic wave of 
specification of OPCs (Naruse et al., 2017). Once specified, OPCs migrate away, under control 
of both repulsive and attractive cues, from the neuroepitheliun of the 
ventricular/subventricular zone of the brain to the developing white matter, where they 
proliferate and form an evenly space network of processing-bearing cells (Simons and Nave, 
2015). While some OPCs find targets and differentiate into myelinating OLs, others remain in 
the adult brain in a precursor state for replacing OLs at a constant rate of turnover or at an 
accelerated level for myelin regeneration. However, due to their electrical properties and their 
participation in synaptic interactions, they may also exert physiological roles in the adult CNS 
(Fancy et al., 2011). 
 
2.1. Oligodendrocyte proliferation 
 
OPC proliferation is regulated by numerous signaling molecules released by neurons or 
other cell types as astrocytes. Several growth factors act as potent mitogens for OPCs. One of 
them is the PDGF-AA, which binds to its receptor PDGFRα. This receptor is abundantly 
expressed in OPCs, and is downregulated as they differentiate into mature OLs (Calver et al., 
1998). The fibroblast growth factor (FGF) controls OPC proliferation extending the time period 
over which OPCs are proliferative and preventing their differentiation into myelinating OLs 
(Mayer et al., 1993). Neurotrophin 3 (NT3) and insulin-like growth factor 1 (IGF-1) are also 
involved in stimulating proliferation of OPCs. However, small hydrophobic signals such as 
thyroid hormone, retinoic acid or glucocorticoids have been reported to stop OPC 






their differentiation (Barres et al., 1994). Moreover, neurotransmitters have been involved in 
the modulation of OPC proliferation, as they receive both excitatory and inhibitory synaptic 
inputs mediated by glutamate and γ-aminobutiric acid (GABA) (Bergles et al., 2000; Lin and 
Bergles, 2004; Karadottir et al., 2008; Vélez-Fort, 2010). For that reason, these 
neurotransmitters are supposed to regulate OPC development. 
 
2.2. Oligodendrocyte differentiation 
 
OPCs go through different stages of cell maturation characterized by changes in the 
expression pattern of molecular markers as well as changes in their morphology. The 
sequential expression of developmental markers divides the lineage into distinct phenotypic 
stages: OPCs or early progenitor cells, immature premyelinating OLs and mature OLs 
(Baumann and Pham-Dinh, 2001; Simons and Nave, 2015). Oligodendroglial lineage cells 
express SOX10 and Olig2 over development, but as OPCs undergo terminal differentiation, 
they lose the expression of specific progenitor markers as PDGFRα and NG2 and begin to 
express immature markers as O4 and galactocerebroside (GalC; Nishiyama et al., 2009). This 
change is accompanied by the development of a more complex shape, a loss of synaptic 
connections and changes in ion channel expression. As they continue progressing in the 
lineage, they begin to express the earliest myelin-related marker, 2´, 3´-Cyclic nucleotide-3´-
phosphodiesterase (CNPase) and adenomatous poliposis coli (APC) marker, also known as CC1. 
Then, as they are mature enough, they express myelin-related  proteins as myelin basic protein 
(MBP), myelin proteolipid protein (PLP), myelin-associated glycoprotein (MAG) and myelin 










Figure 1. Schematic representation of the developmental stages of the oligodendrocyte lineage with 





















OL development and myelination of axons are highly regulated processes by a variety 
of events that involve the participation of negative and positive regulators. These include 
axonal surface ligands, secreted molecules, axonal activity (Emery, 2010) as well as glutamate 
or GABA (Li et al., 2013; Fannon et al., 2015; Zonouzi et al., 2015; Hamilton et al., 2017). 
 
Regarding to the negative regulators, many of axonal expressed ligands are involved in 
preventing OL differentiation or myelination. Among these factors are Jagged, which signals via 
Notch, PSA-NCAM and the Leucine-rich repeat and immunoglobulin domain-containing-1 
(LINGO) (Emery, 2010). The binding of Jagged-1, Delta-1 and-Notch-1 generates an intracellular 
domain that enters in the nucleus and increases the expression of inhibitory transcription 
factors (Wang et al., 1998).  
 
LINGO is a transmembrane protein whose signaling pathways prevent OL 
differentiation by decreasing Fyn kinase activity and subsequent RhoA signaling (Mi et al., 
2005). In addition, canonical Wnt signaling has been described as a potent regulator of OL 
differentiation. Wnt pathway stabilizes β-catenin protein levels, and the constitutive 
expression of β-catenin impairs OPC differentiation and myelination (Fancy et al., 2011). As an 
example, GSK3β negatively regulates OL differentiation via Wnt signaling pathway by 
stimulating nuclear translocation of β-catenin (Azim and Butt, 2011). 
 
In contrast, a variety of diffusible factors positively regulates OL differentiation. 
Besides its participation in OPC survival and proliferation, IGF-1 is also involved in OL 
differentiation and myelination via PI3K/Akt/mTOR signaling pathway (Flores et al., 2008). 
Forced expression of constitutively active Akt or inactivation of phosphatase and tensin 
homolog (PTEN), results in hypermyelination of axons, which is dependent on the activation of 
the Akt substrate mTOR (mammalian target of rapamycin; Fancy et al., 2011). As mentioned 
before, triiodothyronine/thyroid hormone 3 (T3) regulates OL differentiation. Although T3 is 
not ultimately essential for OPCs to differentiate, it plays an important role in the timely and 
efficient production of myelin during development by accelerating OPC differentiation (Mitew 
et al., 2014).  
 
Transcription factors as Olig2 are intracellular regulators of OPC differentiation. Mei et 
al. (2013) demonstrated that ablation of Olig2 in OPCs postnatally causes an important 
decrease in OL differentiation, while it has no detrimental effect on the mature cells, 






factor Myrf is specifically induced during OL differentiation, mediating the transition of 
premyelinating OLs to mature myelinating OLs. Knockdown of Myrf in OLs prevents the 
expression of most myelin genes, and mice in which Myrf function is disrupted within the OL 
lineage show severe demyelination (Emery et al., 2009). 
 
Histone deacetylation is also implicated in OL differentiation. Histone deacetylases 
(HDACs) form complexes that inhibit expression of transcriptional repressors of differentiation 
(Li et al., 2009). 
 
2.3. Oligodendrocyte functions 
 
The main role of mature OLs is the formation of a myelin sheath around CNS axons, 
which provides electrical insulation, decreasing the capacitance and increasing the resistance 
of the axonal membrane. Myelin is essential for rapid action potential propagation, required 
for the correct functioning of the vertebrate CNS. It increases nerve conduction velocity 20 to 
100-fold in comparison with non-myelinated axons. Moreover, it provides fidelity in the 
transmission of signals to long distances, and restricts axonal energy requirements (Baumann 
and Pham-Dinh, 2001). In contrast to the peripheral nervous system (PNS), where Schwann 
cells establish a one-to-one cell connection with the axon, OLs are able to myelinate numerous 
axonal areas, depending on the axon caliber and length. While in the spinal cord some OLs 
form myelin only around one single large axon with an internode (myelin segment) length of 
1500 μm, cells in the cortex and corpus callosum generate between 30 and 80 internodes 
ranging from 20-200 μm (Snaidero and Simons, 2014). 
 
Apart from this well-established function, OLs are crucial for providing trophic and 
metabolic support to axons. They transfer energy metabolites to neurons through cytoplasmic 
“myelinic” channels and monocarboxylate transporters, which permits fast delivery of 
metabolites such as pyruvate and lactate, whose metabolism contributes to ATP synthesis in 
neurons. OLs express specific transporters for glucose-derived metabolites that ensure their 
shuttling toward neurons in order to fuel their energetic demands (Philips and Rothstein, 2017) 





As an example, it is well-known that OLs express monocarboxylate transporter 1 
(MCT1) and that this transporter mediates metabolic support to axons. In fact, OL-specific 
MCT1 depletion produces severe axonal injury and motor neuron death in vivo (Lee et al., 
2012). OL accumulate intracellular lactate which can flow through MCT1 into the periaxonal 
space, where it can be taken up by neurons through MCT2. Furthermore, other metabolites, 
some proteins, neuronal trophic factors or mRNA are transported as well from OLs to axons 
possibly through cytoplasmic myelinic channels to support neuronal activity (Nave and 
Werner, 2014). 
 
N-methyl-D-aspartate receptors (NMDARs) also participate in OL-mediated neuronal 
metabolic support. The OL-neuron lactate shuttle is driven by neuronal activity as glutamate 
released from neurons binds to oligodendrocyte-NMDARs and produces and increase in 
















Figure 2. Oligodendrocytes provide metabolic support to axons (adapted from Philips and Rothstein, 
2017). A) Oligodendrocytes and astrocytes contribute to neuronal metabolic support. B) 
Oligodendrocyte-neuron lactate shuttle is driven by neuronal activity. Neuronal released glutamate 
binds to oligodendrocyte-NMDARs leading to an increase in glucose uptake and its conversion into 
lactate. C) Lactate is transported through MCT1 into the periaxonal space, where is taken up by 











2.4. Myelination by oligodendrocytes 
 
The term “myelin” was coined by Rudof Virchow in 1864 and comes from the Greek 
word “marrow” (myelos), because it is particularly abundant in the core, or marrow, of the 
brain (Snaidero and Simons, 2014). The myelin sheath is separated from the axonal membrane 
by a narrow extracellular cleft (the periaxonal space), and it is a spiral structure constituted of 
extensions of the plasma membrane of OLs, which is interrupted by unmyelinated segments 
rich in voltage-gated Na+ channels, called nodes of Ranvier (Baumann and Pham-Dinh, 2001). 
This allows the action potential to be regenerated at each node, thus propagating from one 
node to the next by saltatory conduction. Regarding to its molecular composition, myelin has 
low water content, a high percentage of lipids, and a small set of proteins that include MBP 
and PLP (the most abundant), CNPase, MAG and MOG (Baumann and Pham-Dinh, 2001; 
Simons and Nave, 2015). 
 
Myelination occurs relatively late in development in a defined temporal sequence. In 
mice, it starts at birth in the spinal cord and is almost completed at postnatal day 60 (P60) in 
most brain regions (Baumann and Pham-Dinh, 2001). In rats, the peak of myelination takes 
place around P20 (Downes and Mullis, 2014) while in humans occurs during the first year of life 
and continues into young adulthood, especially in some cortical areas of the brain (Fields, 
2008). Myelin biogenesis is dynamically regulated by experience and environmental factors 
both during development and in adult life (Fields, 2008; Makinodan et al., 2012; Liu et al., 
2012).  
 
Myelination by OLs is a very well coordinated process that involves the participation of 
a wide variety of inhibiting and promoting signals coming from axons or other cell types as 
astrocytes (Hammond et al., 2014) or microglia and macrophages (Miron et al., 2013). 
Neuronal activity also influences OL differentiation and myelination (Gibson et al., 2014). This 
complex programme is initiated in response to axon-glia recognition and mediated by 
membrane bound cell adhesion molecules that allow OLs to extend their processes towards 
the axon and to start wrapping around it. Then, oligodendroglial cells reorganize their 






Concerning to the axonal-derived signals, polysialylated neural cell adhesion molecule 
(PSA-NCAM) and the adhesion molecule L1 CAM are expressed on the axonal surface at the 
beginning of myelination, being removed as the axon become myelinated (Coman et al., 2005). 
In contrast, the Src family kinases (SFKs) are non-receptor tyrosine kinases that integrate 
neuronal external signals from integrin and growth factor receptors and are involved in OL 
development. One of its members, Fyn, is expressed in both neurons and glia in the brain 
(Colognato et al., 2004) and its signaling downstream pathways regulate the morphological 
differentiation of OLs, the recruitment of cytoskeleton components and the local translation of 
MBP (White and Krämer-Albers, 2014) (Figure 3).  
 
Fyn kinase activity reaches its maximum peak at the beginning of myelination and Fyn-
deficient mice have been reported to show impaired myelination (Umemori, 1994; Sperber et 
al., 2001). During OL maturation, Fyn kinase activity is compartimentalized into lipid raft 
membrane domains with other proteins, to favor their interaction (White and Krämer- Albers, 
2014). Fyn activates in response of axon-glia contact with the participation of the cell adhesion 
molecule L1 and extracellular matrix-derived laminin-2 interacting with integrin β1 and 
contactin-1 OL complex (White et al., 2008). At the cellular level, Fyn activation interferes with 
OL maturation and process outgrowth (Sperber and Morris, 2001) as it mediates netrin-1 
induced process branching. Netrin 1 binds to Dcc receptors in mature OLs and recruits Fyn to a 
complex with the receptor intracellular domain and other proteins, resulting in a decrease in 










Figure 3. Fyn signaling downstream pathways (adapted from White and Krämer-Albers, 2014). Fyn 
kinase associates with lipid rafts and is activated by axonal signals triggering different signaling 
pathways that regulate morphological differentiation of OLs, cytoskeleton recruitment and local 






Neuregulins (NRGs), which bind to ErbB tyrosine kinase receptors in OLs, have also 
been reported to participate in the survival and differentiation of these cells (Park et al., 2001). 
However, its role in myelination still remains under debate as both NRG and ErbB receptor 
knockout mice show normal myelination (Brinkmann et al., 2008). Other signaling pathways, 
such as PI3K/Akt/mTOR, Erk1/2-MAPK pathways and CAMKIIβ signaling are important 
regulators of the myelination process (Flores et al., 2008; Guardiola-Díaz et al., 2012; White 
and Krämer-Albers, 2014). 
 
Neurotransmitters also participate in the regulation of myelination (Li et al., 2013; 
Hamilton et al., 2017). OPCs receive both glutamatergic and GABAergic synaptic inputs 
(Bergles et al., 2000; Lin and Bergles, 2004; Karadottir et al., 2008; Fannon et al., 2015; Zonouzi 
et al., 2015) and this communication between individual axons and OPCs promotes myelin 
formation in electrically active ones. Kukley et al. (2007) described that OPCs establish 
excitatory glutamatergic synapses with unmyelinated axons suggesting that it may play a role 
in controlling the development of myelination. Moreover, Wake et al. (2011) showed that 
glutamate release from synaptic vesicles promoted myelination by increasing the local 
synthesis of MBP in OLs. In turn, GABA controls myelination in vitro (Hamilton et al., 2017), and 
as the expression and function of GABAA receptors (GABAARs) in cultured OLs is driven by 
axonal cues, GABA signaling may play a relevant role during axon-glia recognition and in 
myelination (Arellano et al., 2016). However, these findings in vitro await confirmation in vivo. 
 
In addition to the axonal signals, differentiation of OLs and myelination are regulated 
by transcription factors. The transcription factor cyclic-AMP response element binding protein 
(CREB) plays an important role in these processes as it acts as a mediator in the c-AMP 
dependent stimulation of MBP (Afshari et al., 2001). However, apart from its role as a cAMP-
responsive activator, CREB can be phosphorylated and promote cellular gene expression in 
response to both extracellular and intracellular signals involving the participation of multiple 
protein kinases (Mayr and Montminy, 2001; Mao et al., 2007). 
 
3.    MULTIPLE SCLEROSIS  
 
Multiple sclerosis (MS) is a chronic, inflammatory and demyelinating disease of the 




from 1954, became MS in the English literature (Figure 4; Zalc, 2018). Among the different 
demyelinating diseases, MS is the most prevalent in young adults, affecting more than 2 
million people worldwide (Reich et al., 2018) and being more common in women than men 











MS is a heterogeneous neurological disease both clinically and pathologically that 
causes irreversible physical and mental disability. It is characterized by focal lesions, named 
sclerotic plaques, with an autoimmune attack to the myelin sheath, leading to OL degeneration 
and demyelination, gliosis and axonal damage (Compston and Coles, 2008; Dendrou et al., 
2015). Demyelination results in slower conduction velocity or complete failure of transmission, 
causing neuronal dysfunction and the appearance of diverse signs and symptoms that vary 
within each affected CNS area. These sclerotic plaques can appear both in the white and grey 
matter, brain stem, spinal cord, cerebellum or optic nerve (Reich et al., 2018) producing motor, 
sensory and cognitive deficits. Among the symptoms and signs in MS are: optic neuritis, 
dysarthria, fatigue, dysphagia, spasticity and muscle weakness, paresthesia, tremor, painful 
spasms, the characteristic Lhermitte´s symptom, which consist of and electrical sensation 
running down the spine or limbs on neck flexion, and the Uhthoff phenomenon, a transient 
worsening of symptoms and signs when body temperature increases, as occurs after doing 
exercise or having a hot bath (Compston and Coles, 2008). 
 
Although it is still unknown whether MS has a single or multiple causes, it is widely 
accepted that both genetic and environmental factors are implicated in the development of 
the disease (Huynh and Casaccia, 2013; Reich et al., 2018). Genomewide association studies 
have identified more than 200 gene variants that increase the risk of MS, being the most 
significant the human leukocyte antigen (HLA) DRB1*1501 haplotype. Numerous risk alleles 
are associated with immune-pathway genes, a fact that is consistent with the idea that an 
Figure 4. Original drawing from Charcot’s notebook illustrating the limit of a lesion in the 
protuberance with handwritten legends on the right. A: Periphery outside the plaque. B: The plaque. 






autoimmune mechanism participates in the pathogenesis of the disease (Reich et al., 2018). 
The environmental risk factors include geographical latitude, vitamin D levels, tobacco 
exposure, obesity in early life and infection with the Epstein-Barr virus (Ascherio and Munger, 
2016). Recent studies have also proposed an important influence of gut microbiota in the 
propensity for development of experimental autoimmune encephalomyelitis (EAE), the mouse 
model of MS (Berer et al., 2017; Cekanaviciute et al., 2017), suggesting that individual 
differences in the composition of the microbiota may affect the immune system by modulating 
the equilibrium between different subclasses of lymphocytes. 
 
3.1. Etiology of MS 
 
Tissue damage in MS is the consequence of a complex and dynamic interplay between 
immune cells, glia and neurons. Without a known root cause of MS, there is a debate about 
whether its origin is extrinsic (“outside-in” theory) or intrinsic (“inside-out” theory) to the CNS  
and whether the immune cell infiltration precedes or not demyelination and axonal 
degeneration (Tsunoda and Fujinami, 2002; Matute and Pérez-Cerdá, 2005; Reich et al., 2018) 
(Figure 5).  
 
The most accepted view is that abnormal autoimmune responses, possibly triggered 
after viral infections, are responsible for the demyelination and the subsequent 
neurodegeneration that occurs in MS (Kipp et al., 2012; Geginat et al., 2017). In this “outside-
in” theory, activated immune T cells enter the CNS by crossing the blood brain barrier (BBB). 
Once there, they become autorreactive and destroy myelin directly by releasing toxins and 
cytokines or indirectly by inducing activation of microglia and recruiting other cell types from 
the periphery as macrophages, activated B cells, monocytes, dendritic cells and natural killer T 
cells. Then, myelin loss leads to OL degeneration and axonal injury (Matute and Pérez-Cerdá, 
2005; Lopez-Diego and Weiner, 2008) (Figure 5A). This theory supports the use of the EAE 
murine model to study MS.  
 
On the contrary, the “inside-out” theory defends that OL degeneration is the primary 
event that takes place in MS. This theory is based on a study of Barnett and Prineas (2004) in 
which they found OL apoptosis and microglial activation in the absence of a clear immune 
response in lesions from patients who died during or immediately after the onset of a fatal 




glutamate-derived excitotoxicity (Matute et al., 2001; Werner et al., 2001), oxidative stress or 
signals generated during hypoxia can induce OL apoptosis and primary axonal degeneration 
and, as a consequence, the resulting myelin debris can activate microglia and peripheral 
immune cells (Figure 5B). Thus, the immune response constitutes a secondary event in this 


















Although the prevailing view is the “outside-in” theory, both models could act 
simultaneously initiating a cascade of events and contributing to the pathogenesis of the 
disease. 
 
3.2. MS subtypes 
 
MS is highly heterogeneous in terms of disease course and symptoms, and it is 
commonly classified into subtypes (Dendrou et al., 2015). In 1996, Lublin and Reingold 
classified MS into four clinical courses defined as relapsing-remitting MS (RRMS), primary 
progressive MS (PPMS), secondary progressive MS (SPMS) and progressive-relapsing MS 
(PRMS) (Lublin and Reingold, 1996). This classification has allowed better communication of 
Figure 5. Alternative theories of lesion formation in MS. A) “Outside-in” theory: activated T cells enter 
the CNS (1) become autorreactive and destroy myelin directly by releasing toxins and cytokines or 
indirectly by inducing activation of microglia and recruiting macrophages from the periphery. This leads 
to myelin destruction, OL death and clearance of damaged tissue by phagocytes (2). (B) “Inside-out” 
theory: several factors can induce OL apoptosis (1) and large amounts of myelin debris are generated 
(2) exceeding the capacity of the phagocytic cells to clear them and triggering inflammation. 
Consequently, T cells and macrophages invade the CNS (3) and initiate the autoimmune attack of myelin 







patient´s clinical courses and to define clinical trial populations. However, a better 
understanding of MS and its pathology will surely lead to a redefinition of this current 
classification. The revised criteria by Lublin considers disease activity, based on clinical relapse 
and magnetic resonance imaging (MRI) findings, and disease progression; adding the clinically 
isolated syndrome (CIS) and removing the PRMS (Lublin, 2014). Thus, the current 
categorization of MS establishes the following subtypes (Figure 6): 
 
 Clinically isolated syndrome (CIS): it is the first clinical manifestation and consists of an 
acute or subacute episode of neurological disturbance attributed to a single white matter 
lesion. This could be the onset of MS or an isolated clinical event. When CIS is 
accompanied by MRI abnormalities and cerebrospinal fluid (CSF) criteria, the probability 
of developing MS is higher. MS can be diagnosed within 3 months of CIS presentation 
(Miller et al., 2005). 
 
 Relapsing-remitting MS (RRMS): it is the most common form, affecting approximately 85% 
of patients. It is characterized by CIS followed by unpredictable recurring attacks with 
partial or total neurological recovery. Relapses coincide with focal CNS inflammation and 
demyelination that are typically distinguishable by MRI as white matter lesions (Dendrou et 
al., 2015; Filippi et al., 2018). Normally, disability accumulates with each relapse and most 
of the patients go on to develop secondary progressive MS. 
 
 Secondary progressive MS (SPMS): in this subtype, inflammatory lesions are no 
characteristic as progressive and irreversible disability occurs independently of the 
presence of relapses. Basically, neurological decline is accompanied by CNS atrophy, which 
consists of a decreased in brain volume as axonal loss progresses. Approximately 80% of 
RRMS patients develop SPMS (Dendrou et al., 2015; Filippi et al., 2018). 
 
 Primary-progressive (PPMS): between 10-15% of patients present a gradual, continuous 
and progressive neurological decline from the onset in absence of relapses (Dendrou et al., 
2015; Filippi et al., 2018). 
 
Apart from that, a recent study by Trapp et al. (2018) suggests a new subtype of MS 




demyelination without affecting cerebral white matter. In this study, they propose that cortical 















3.3. Pathophysiology of MS 
 
The pathological hallmark of MS is the accumulation of focal areas of demyelination 
and OL death in the white and grey matter of the brain and spinal cord known as plaques or 
lesions (Filippi et al., 2018). In the white matter, active lesions are accompanied by 
inflammation and glial reaction (Reich et al., 2018). At the early stages of the disease axons 
and neurons are preserved but, as it progresses, a gradual axonal loss occurs and correlates 
with clinical disability. This phenomenon results in brain atrophy with ventricular enlargement 
(Dendrou et al., 2015). 
 
In the early phase of the disease, there is little damage outside focal lesions, termed 
normal-appearing white matter, although general brain atrophy is also noticed. As the disease 
progresses, diffuse myelin decrease and axonal injury become evident, resulting in a more 






Figure 6. Diagram representing the clinical course of MS showing the progression of disability (Filippi 
























The disease starts with the breakdown of the BBB, which involves the infiltration of 
different types of immune cells from the periphery to the CNS. Pro-inflammatory molecules 
secreted by resident cells and endothelial cells, and leukocyte-mediated injury provoke the 
disruption of the BBB (Ortiz et al., 2014), leading to the infiltration of both helper (CD4+) and 
cytotoxic (CD8+) T cells, as well as B cells and macrophages (Filippi et al., 2018; Reich et al., 
2018). While T cells are reactive to myelin antigens, B cells can adopt different roles. Besides 
secreting CNS-directed autoantibodies, B cells can also present antigens to helper T cells and 
release cytokines, contributing to exacerbate inflammation (Michel et al., 2015). Microglia and 
astrocytes become activated with the progression of the disease. Astrocytes form multiple glial 
scars in the white matter lesions. They can enhance inflammation by releasing effector 
molecules, but, on the other hand, they may also limit damage by removing glutamate, 
providing metabolic support to axons and maintaining the BBB (Ludwin et al., 2016). Thus, 
there is a complex inflammatory process that is present at all stages of the disease, but is more 
prominent in the acute than in the chronic phases (Dendrou et al., 2015). Activated microglia 
and macrophages become pathologically indistinguishable. These cells play dual roles as they 
sometimes mediate inflammation but in other circumstances, promote myelin repair by 
Figure 7. The pathology of MS in the spinal cord (A) and in the brain (B) (transverse spinal cord view
and coronal brain view, respectively; adapted from Dendrou et al., 2015). Red: white matter lesion; dark 






clearance of myelin debris (Aguzzi et al., 2013; Yamasaki et al., 2014) or contributing to OL 
differentiation (Miron et al., 2013). 
 
Following demyelination, which may be the consequent of the aberrant immune 
response, the myelin sheath is lost but the underlying axon remains intact. This allows the 
formation of the regenerative response, which is called remyelination. This process consists of 
the generation of new myelin sheaths from newly formed OLs, since existing ones with 
damaged sheaths do not contribute to myelin restoration (Franklin and ffrench-Constant, 
2017). The MS lesions that undergo remyelination are called shadow plaques (Franklin, 2002). 
 
Two immature cell populations have been involved in promoting remyelination. OPCs, 
which are able to differentiate into mature myelinating OLs, and adult NSCs, which are known 
to contribute to adult oligodendrogenesis at least in animal models (Xing et al., 2014). In 
response to white matter injury, OPCs migrate at the edge of the lesion, where they enter the 
cell cycle and expand. Then, they undergo differentiation, a process that concludes with the 
formation of new myelin sheaths that are thinner and with shorter internodes than those 
formed during development (Blakemore, 1974). It seems that myelin is patched up rather than 
restored (Fancy et al., 2011). As occurs in myelination during development, remyelination is 
also strongly influenced by several molecules. Microglia, macrophages and astrocytes are 
major sources of factors that promote OPC activation, proliferation and migration (Franklin 
and ffrench-Constant, 2017). However, OPCs often fail to differentiate (Kotter et al., 2006; 
Kuhlmann et al., 2008) and/or newly formed OLs fail to wrap myelin, and remyelination fails, 
as occurs in the chronic phases of MS. Consequently, axonal conduction cannot be restored 
and the supportive role of myelin is lost. This leads to mitochondrial dysfunction and energy 
deficiency, impaired axonal transport, and ultimately axonal degeneration that can then elicit a 
secondary immune response (Franklin and ffrench-Constant, 2017; Reich et al., 2018) (Figure 
8). 
 
Furthermore, Franklin (2002) proposed a hypothesis for remyelination failure in which 
the signaling environment becomes “dysregulated”. According to this hypothesis, 
remyelination fails due to a loss of coordination in this complex and harmonized mechanism 
(Fancy et al., 2011). Whatever happens, remyelination failure represents a severe problem in 
MS, being the development of drugs that enchance remyelination and attenuate 

















3.4. Experimental animal models of MS 
 
The complexity and incomplete understanding of MS requires the use of experimental 
animal models to further study the disease. Although there are several animal models that 
reproduce different aspects of MS, none of them recapitulate all the features of its 
pathophysiology.  
 
3.4.1. Experimental autoimmune encephalomyelitis (EAE) 
 
EAE is the most widely applied animal model of MS and reproduce the inflammatory 
aspects of the disease. It can be induced by two different protocols, which are the 
administration of activated T-lymphocytes that act specifically against myelin antigens or, 
more frequently, by the inoculation of myelin-derived peptides solubilized in Freund´s 
adjuvant solution (Palumbo and Pellegrini, 2017). This produces and immune response against 
the myelin of the CNS that is predominantly mediated by CD4+ T helper 1 (Th1) and Th17 cells 
(Ben et al., 1981; Liblau et al., 1995; Bettelli et al., 2005), although CD8+ T cells are also 
present. The addition of the pertussis toxin to the injection mixture facilitates the migration of 
the lymphocytes across the BBB. Activation of microglia, macrophages and astrocytes also 
occurs in this model. 
 
The peak of demyelination is reached between 10-15 days after injection and is 
primarily confined to the spinal cord, whereas in MS inflammatory lesions are mostly found in 
the brain (Dendrou et al., 2015). EAE animals develop a progressive paralysis that starts from 
the tail and continues to the hind limbs and ultimately the front limbs (García-Díaz and Estivill-
A B C 
Figure 8. Major steps required for remyelination. Following demyelination (A), OPCs are recruited into 
the lesion site and then differentiate into myelinating OLs (B). However, they form new myelin sheaths 
that are thinner and with shorter internodes than those formed during development (C). The 




Torrús, 2008; Palumbo and Pellegrini, 2017). The clinical course varies with the 
immunopeptide and the animal strain used. While immunization with MOG peptide in C57BL/6 
mice causes a chronic progressive disease (Slavin et al., 1998), EAE induced with PLP peptide in 
SJL/J mice follows a relapsing-remitting course (Tuohy et al., 1989). 
 
New transgenic and engineering technologies in combination with advances in imaging 
are expanding the potential utility of EAE, which is considered a good model to test 
immunosuppressive therapies. However, it constitutes a reductive model that needs to be use 
and interpreted with care (Dendrou et al., 2015). 
 
3.4.2. Virus-induced inflammatory demyelination 
 
Viral infections may be directly or indirectly involved in the initiation of MS (Geginat et 
al., 2017). Although no MS-specific viral infection have been found, virus induced experimental 
models of inflammatory demyelination may serve to better understand the basic mechanisms 
of the disease.  
 
Among the viruses that can produce demyelination in the CNS, the best studied is the 
Theiler’s murine encephalomyelitis virus (TMEV). In this case, chronic demyelinated 
encephalomyelitis is induced by direct intracerebral infection of the animals with the virus. 
This leads to an acute encephalomyelitis followed by demyelination mainly in the spinal cord. 
The disease course and mortality depend on the virulence of the virus strain used and the 
genetic background of the host animals (Lassmann and Bradl, 2017). The lesions are 
characterized by chronic inflammation, confluent plaques of demyelination, OL apoptosis, 
axonal damage and remyelination (Rodriguez et al., 1987). Inflammatory infiltrates contain a 
mixture of CD4+ and CD8+ T cells, B cells and plasma cells (Tsunoda et al., 2007) and there is 
also activation of microglia and macrophages. Thus, lesions are similar to those present in MS. 
Another virus is the mouse hepatitis (corona) virus (MHV), whose JHM strain causes acute 
encephalitis and chronic demyelination (Bender and Weiss, 2010). 
 
3.4.3. Toxin-induced demyelination 
 
Given that primary demyelination is the main pathological hallmark in MS and pre-
existing OLs do not contribute to myelin restoration, we need to identify new therapeutic 






(Lassmann and Bradl, 2017). However, due to the limitations of studies in human tissue, 
researchers have focused on animal models to investigate remyelination. Models of toxic 
demyelination allow the study of the fundamental biology of remyelination without the 
complicate involvement of an autoimmune process (Franklin and ffrench-Constant, 2017). 
These models are based on the administration of bioactive molecules that specifically targets 
OLs leading to their degeneration and death, and the subsequent demyelination. Various 
toxins like cuprizone, lysolecicithin (or lysophosphatidylcholine, LPC) and ethidium bromide 
efficiently trigger CNS demyelination (Palumbo and Pellegrini, 2017). 
 
Cuprizone (bis-cyclohexanone oxalhydrazone) is a neurotoxic copper chelator that 
impairs cytochrome oxidase activity in OL mitochondria causing apoptosis. The BBB remains 
intact and no signs of lymphocyte infiltration have been observed (Kremer et al., 2019), while 
microgliosis and astrogliosis are present (Matsushima and Morell, 2001). Oral administration 
of cuprizone in mice results in grey and white matter demyelination, especially in the corpus 
callosum and the superior cerebellar peduncles but not in the spinal cord. After cuprizone 
removal from diet, spontaneous remyelination occurs via oligodendrogenesis. In contrast, 
prolonged administration impairs remyelination as in progressive MS (Palumbo and Pellegrini, 
2017). 
 
Lysolecithin can be injected in several areas of the CNS, as the corpus callosum (Lehto 
et al., 2017), the lateral ventricle (Azim and Butt, 2011), the optic nerve (Mozafari et al., 2010) 
or the spinal cord (Tepavcevic et al., 2014). It induces focal plaques of demyelination due to a 
direct detergent action against the lipid membrane-rich myelin sheath (Jeffery and Blakemore, 
1995) and subsequently, OL death. This rapidly leads to OPC recruitment followed by 
differentiation and remyelination, although the speed and degree of remyelination are age-
dependent (Franklin et al., 2002; Crawford et al., 2013). LPC-induced demyelination occurs 
independently of immune response and involves the infiltration of T cells, B cells and 
macrophages, which is suggested to be beneficial for starting remyelination (Bieber et al., 
2003). Macrophages are proposed to clear the myelin debris that prevents remyelination 
(Kotter et al., 2001). This model allows the study of demyelination and remyelination in 
different CNS regions without the complication of an autoimmune response and is useful for 
searching new potential therapies that enhance remyelination, which constitutes the major 




A similar time course of demyelination and remyelination can be attained by injecting 
ethidium bromide into white matter tracts, causing OL and astrocyte degeneration 
(Blakemore, 1982). Compared to LPC, the last is less toxic for astrocytes and allow 
demyelination and the subsequent repairing response in a shorter period of time. Hence, both 
LPC and ethidium bromide constitute an appropriate toxin for inducing local and acute 
demyelination in the CNS (Mozafari et al., 2010). 
 
3.5. Treatments for MS 
 
There is no definitive cure for MS at present, but there are a wide range of 
pharmacological treatments that attenuate its symptoms and slow down its progression. 
These treatments are classified into disease-modifying therapies that used to be MS-specific 
and reduce inflammatory disease activity or relapses frequency; and symptomatic treatments 
that are not specific for MS and are used for short-term amelioration of the different 
symptoms of the disease (Filippi et al., 2018; Dobson and Giovannoni, 2019). 
 
Disease-modifying treatments (DMTs) are basically immunosuppressant or 
immunomodulatory therapies that should be administered as soon as possible in order to 
minimize the risk of disease progression and prevent long-term disability. Thus, injectable 
interferon beta (IFNβ) and glatiramer acetate have been widely used as first-line treatments, 
however, they have only moderate clinical effectiveness and poor tolerability due to injection-
related adverse reactions as flu or inflammation. The predominant current therapeutic 
strategy for RRMS is called escalation therapy. It consists of starting with safe but moderately 
effective DMTs as IFNβ, glatiramer acetate, teriflunomide or dimethylfumarate and then 
switching to another DMT in patients with intolerable side effects, or to a more effective one 
in those with new relapses. For patients who do not respond to traditional DMTs, 
hematopoietic stem cell transplantation might be indicated (Muraro et al., 2017). Another 
strategy is named induction therapy and has appeared due to the need to treat patients earlier 
with more effective drugs, such as alemtuzumab or ocrelizumab, to prevent the accumulation 
of CNS damage and clinical disability (Filippi et al., 2018). This strategy is indicated for patients 
with severe and frequent relapses and a higher number of MRI lesions. Fingolimod and 
natalizumab are also high-efficacy treatments but do not exert a considerable immune reset.  
 
Regarding to progressive disease forms, the anti-CD20 DMTs ocrelizumab and 






al., 2017), and are a better option than the cytostatic drug mitoxantrone, which was approved 
by the US Food and drug administration (FDA) in 2000 but has a limited use due to its 
cardiotoxic and mutagenic adverse effects (Hartung et al., 2002).  
 
Relapses are usually treated with high-dose corticosteroids, but for those that do not 
respond to this treatment, plasma exchange or intravenous immunoglobulin might be an 
alternative (Filippi et al., 2018). 
 
Symptomatic treatments refer to numerous pharmacological agents and physical 
therapies prescribed to treat the different symptoms that arise as a consequence of CNS 
damage. However, for most of them there is no strong evidence of clinical efficacy (Dobson 
and Giovannoni, 2019). Anticholinergic drugs are indicated for bladder dysfunction, although 
they may induce cognitive impairment. Neuropathic pain is usually treated with 
gabapentinoids like gabapentin and pregabalin or antidepressants. Opioids are second-line 
treatments for moderate to severe pain, while cannabinoids can be recommended as a third-
line option (Moulin et al., 2014). Spasticity is another common symptom of the disease that is 
targeted with cannabinoids, such as the mucosal spray nabiximol (Sativex) (Collin et al., 2010), 
or other drugs as baclofen, diazepam and tizanidine, although their effectiveness are at stake 
(Shakespeare et al., 2003). The GABAB receptor (GABABR) specific agonist baclofen can be 
administered orally (at higher doses) or intrathecally at lower doses with less adverse effects 
(Ertzgaard et al., 2017). Dalfampridine is a voltage-dependent potassium channel blocker that 
enhances the transmission of nerve impulses in demyelinated axons improving the walking 
ability of MS patients (Goodman et al., 2010). For the management of fatigue, vitamin D 
analog alfacalcidol provides clinical benefit (Achiron et al., 2015). Physical exercise is also 
recommended (Dobson and Giovannoni, 2019). 
 
Besides that, the major therapeutic challenge is to promote endogenous remyelination 
by stimulating OPC differentiation and improving the capacity of mature OLs to wrap naked 
axons. In this sense, there are several remyelinating therapies under clinical trials such as 
histamine H1 receptor blocker clemastine, the antibody anti-LINGO-1 opicinumab, statins 
(simvastatin) which are extensively used to treat hypercholesterolemia, vitamin B family 
coenzyme biotin, the antipsychotic drug quetiapine, the D2/D3 dopamine receptor antagonist 





4. THE GABAERGIC SYSTEM 
 
4.1. GABA synthesis and metabolism 
 
The amino acid GABA is the main inhibitory neurotransmitter in the vertebrate CNS 
(Angulo et al., 2008), though it exerts an excitatory function in the immature brain (Ben-Ari, 
2002). It is not restricted to the CNS as GABA and its receptors are also expressed in the PNS 
and in non-neuronal systems such as adrenal glands, kidney, liver, pancreas, stomach and gut, 
ovary and uterus, semen or urinary bladder (Erdö, 1992) as well as in the immune system (Bhat 
et al., 2009). 
 
GABA can be synthesized through two different pathways. On one hand, as firstly 
demonstrated by Roberts and Frankel (1950), it is synthesized by decarboxylation of glutamate 
(Glu) by glutamic acid decarboxylase (GAD) enzyme. There are two isoforms of GAD, GAD65 and 
GAD67, with 65 and 67 kDa of molecular weight respectively, and with different catalytic and 
kinetic properties as well as subcellular localization (Kaufman et al., 1991). On the other hand, 
GABA can be produced from putrescine via an alternative pathway that does not involve 
glutamic acid as an intermediate (Seiler et al., 1973). In this case, at least in glial cells, 
putrescine is first acetylated to monoacetyl putrescine and further degraded to GABA by 
monoamino oxidase B (MAOB) enzyme (Angulo et al., 2008; Yoon et al., 2014). Putrescine is 
detectable in mouse brain and liver (Seiler and Askar, 1971) (Figure 9). 
 
Degradation of GABA needs GABA-transaminase (GABA-T), which is a pyridoxal 
phosphate-dependent enzyme, as well as GAD. It converts GABA to succinic semialdehyde 
(SSA) by transamination with the co-substrates glutamate and α-ketoglutaric acid (α-KG). 
Consequently, SSA is oxidized by SSA dehydrogenase (SSADH) to succinate, an intermediary of 
the tricarboxylic acid cycle (TCA; Figure 9) (Angulo et al., 2008; Rowley et al., 2012). GABA-T is 























4.2. GABA receptors  
 
GABA acts through three major classes of receptors, which have been identified on the 
basis on their pharmacological and electrophysiological properties: two types of 
heteropentameric ligand-gated chloride channels, named GABAA receptors (GABAARs) and 
GABAC receptors (GABACRs); and GABAB receptors, which are metabotropic or G protein-
coupled receptors (GPCRs) (Enz, 2001; Frangaj and Fan, 2018).  
 
 Human ionotropic GABARs are encoded by nineteen genes from the human genome 
(Simon et al., 2004). These include sixteen subunits combined as GABAARs (α1-6, β1-3, γ1-3, δ, ε, θ 
and π) and three ρ subunits that contribute to GABACRs, which were originally described in the 
mammalian retina based on a characteristic pharmacology that did not fit either the “A” or the 
“B” category (Polenzani et al., 1991; Olsen and Sieghart, 2008). Compared to GABAARs, 
GABACRs have higher sensitivity for GABA, their currents are smaller and they do not seem to 
desensitize. At the single channel level, they have longer mean open times and smaller 
chloride conductance (Enz, 2001). 
 
GABAARs are the targets of numerous clinically important drugs like benzodiazepines 
(BZs), barbiturates, anesthetics and convulsants that allosterically modulate GABA-induced 
currents through different binding sites (Sieghart, 1995). This fact makes GABAARs extremely 
complex pharmacologically. Knowing the location and structure of these multiple binding sites 
is required for understanding their modulation by the drugs (Sieghart, 2015). GABAARs are 
activated by GABA and the selective agonist muscimol, a natural product from the mushroom 
Figure 9. GABA synthesis and GABA metabolism. GABA can be synthesized from glutamate (Glu) 
through the action of GAD65 or GAD67 or, alternatively from putrescine, which requires the 
participation of MAOB enzyme. GABA is metabolized by GABA-transaminase (GABA-T) (adapted from 




Amanita muscaria; while bicuculline, picrotoxin and gabazine are among its selective 
antagonists (Macdonald and Olsen, 1994; Johnston, 2013). 
 
The existence of such a variety of GABAAR subunits give rise to a multiplicity of 
receptor subtypes with different subunit composition and specific pharmacological properties 
(Olsen and Sieghart, 2008), although most GABAARs expressed in the brain are composed of 
2α, 2β and 1γ2 subunit. The five subunits form a central chloride channel. Each subunit holds a 
large N-terminal extracellular domain, four transmembrane domains (TMs) each forming an α-
helix, a large intracellular loop between TM3 and TM4, which is the site for several protein 
interactions and post-translational modifications, and a short extracellular C-terminus 
(Schofield et al., 1987; Jacob et al., 2008). A study of GABAAR subunits by Tretter et al. (1997) 
showed that α and β alternate with each other and are connected by the γ subunit. Moreover, 
each subunit has a plus (+) and a minus (-) side, being the two GABA-binding sites located at 
the extracellular β+α- interfaces, and the benzodiazepine one at the extracellular α+γ- 

















GABAARs are differentially expressed throughout the brain and mediate fast inhibitory  
neurotransmission. Binding GABA results in a rapid influx of Cl- into the cell and BZs binding 
potentiates this effect. GABAARs composed of α (1-3) with β and γ subunits are thought to be 
localized mainly synaptically, whereas α5βγ and α (4 or 6)βδ are extrasynaptic (Jacob et al., 
A B 
Figure 10. GABAA receptor structure. A) GABAAR is composed of five subunits from seven subfamilies 
(α, β, γ, δ, ε, θ and π) that assemble to form a heteropentameric Cl
-
 permeable channel. Most GABAARs 
expressed in the brain consist of 2α, 2β and 1γ2 subunit; the γ can be replaced by δ, ε, θ or π. Binding of 
GABA occurs at the interface between the α and β subunits promoting the opening of the channel and 
allowing a rapid influx of Cl
- 
into the cell. BZ binding takes place at the interface between α and γ 
subunits and potentiates GABA-induced Cl
- 
influx. B) GABAAR subunits consists of four hydrophobic 
transmembrane domains (TM1-4), a large extracellular N-terminus which is the site of GABA binding or 
some psychoactive drugs, a large intracellular domain between TM3 and TM4 that is the site for protein 
interactions and post-traslational modifications that modulate receptor activity, and a short 







2008). These receptors are assembled in the endoplasmic reticulum (ER), a process cautiously 
regulated by classical chaperones. Degradation of homomeric unassembled subunits by 
ubiquitylation also occurs in this organelle (Bedford et al., 2001), and can be regulated by 
neuronal activity (Saliba et al., 2007). After their assembly in the ER, GABAARs are trafficked to 
the Golgi apparatus and divided into vesicles for transportation and insertion into the plasma 
membrane. This process is promoted by a variety of GABAAR-associated proteins. In neurons, 
GABAARs undergo extensive endocytosis in a clathrin-dependent manner (Kittler et al., 2000). 
Once endocytosed, most of them are recycled back to the plasma membrane over short time 
frames, while over long time periods they are degraded in lysosomes (Jacob et al., 2008). 
 
On the other hand, GABAB receptors (GABABRs), first discovered in 1979 by Bowery et 
al., are heterodimeric G protein-coupled receptors (GPCR) that mediate slow and prolonged 
inhibitory transmission. The GABAB receptor signaling pathways can involve different effector 
proteins as voltage-gated Ca2+ channels, G-protein activated inwardly-rectifying K+ channels 
(GIRK) and adenylate cyclase system (Frangaj and Fan, 2018), and their downstream effects 
include blockade of neurotransmitter release and hyperpolarization of neurons (Bowery et al., 
2002; Bettler et al., 2004). However, the precise coupling of GABAB receptor to the molecular 
effector can vary depending on the cell type and region analyzed (Booker et al., 2018).  
 
 Two major GABABR isoforms, GABAB1 and GABAB2, have been described (Bettler et al., 
2004; Bettler and Tiao, 2006). In CNS neurons, GABAB1 and GABAB2 are widely co-expressed 
and were found to generate functional receptors in a heterodimeric assembly (Kaupmann et 
al., 1998; Kuner et al., 1999; Marshall et al., 1999). While GABAB1 binds orthosteric ligands, 
GABAB2 couples with G protein and contains the allosteric ligand-binding site. The receptors are 
composed of three domains, a large N-terminal extracellular domain that contains a Venus 
flytrap-like structure (VFT), a seven-helix transmembrane (TM) domain, and a cytoplasmic tail 
with a leucine zipper forming a coiled-coil domain (Benke et al., 2012; Frangaj and Fan, 2018). 
Two variants of GABAB1, GABAB1a and GABAB1b have been identified by molecular cloning 
(Kaupmann et al., 1998). While GABAB1a is predominantly found in the presynaptic terminal, 
GABAB1b is associated with the postsynaptic one and differ by the presence of two complement 
control protein (CCP) modules or sushi domains in the N-terminus of GABAB1a.  The VFT module 
of each GABABR subunit contains two domains or lobes called L1 and L2. Binding of an agonist 




interdomain cleft remains open. Despite these differences, both subunits cooperate with each 
other to perform signal activation (Frangaj and Fan, 2018) (Figure 11). 
 
The orthosteric ligand-binding site of GABABRs can accommodate various agonists 
without altering ligand affinity. These orthosteric ligands are usually derivatives of GABA. 
GABA and the clinical drug R-baclofen are two of the best understood GABABR agonists and 
they are thought to bind via their carboxylic group to the hydroxyl groups of S246 and Y366 
(Bettler et al., 2004). On the other hand, there have been described a large range of 
antagonists with low and high affinities for the GABABR. The attachment of 3,4-dichlorobenzyl 
or 3-carboxybenzyl substituents to the existing molecules produced compounds with affinities 
about 10.000 times higher than previous antagonists, which is the case for CGP55845 (Bowery 
et al., 2002).  
 
The activity of GABABRs can be regulated by allosteric modulators binding to the TM 
domain of the GABAB2 subunit. They are classified into three categories: postitive (PAMs), 
negative (NAMs) and neutral allosteric modulators. The last ones compete with PAMs and 
NAMs for specific sites without modifying receptor activity. Moreover, Ca2+ increases the 
affinity of GABA to the receptor and enhances G protein activation. However, this allosteric 

















Figure 11. GABAB receptor structure. A) GABABRs are GPCRs with a central core domain constituted of 
7 TM helices. They are obligatory heterodimers formed by GABAB1 and GABAB2 subunits. While GABAB1 
subunit contains the large extracellular domain that binds GABA, the GABAB2 subunit couples the 
receptor with the effector G protein (predominantly Gi/o). Their inhibitory effect is via inhibition of 
adenylyl cyclase and presynaptic Ca
2+
 channels, and activation of postsynaptic K
+
 channels. B) Detail of 
the GABABR subunits. There are two isoforms of GABAB1 subunits, named GABAB1a and GABAB1b that 







Surface expression of GABABRs is regulated by the intracellular domain. The GABAB1 
subunit is only transported into the cell surface when it is chaperoned by GABAB2 in a 
heterodimeric pair. This subunit is confined in the ER by the membrane protein PRAF2, exiting 
the organelle only when PRAF2 is displaced by GABAB2. Thus, the assembled heterodimer goes 
to the Golgi apparatus and then to the cell surface, where the receptor can function (Doly et 
al., 2016). GABABRs display fast constitutive internalization, being endocytosed via the clathrin 
and dynamin-dependent pathway. They are predominantly recycled back to the plasma 
membrane and a small fraction is degraded in lysosomes (Benke et al., 2012). 
 
Regarding to its desensitization, three different mechanisms have been described. In 
cerebellar granule cells, G protein receptor kinase (GRK) 4 and 5 associate with the receptors 
and induce its desensitization in a phosphorylation-independent manner (Perroy et al., 2003), 
while in cortical and hippocampal neurons this process implicates the participation of NEM-
sensitive fusion protein (NSF) and PKC (Pontier et al., 2006). Some members of the potassium 
channel tetramerization domain-containing (KCTD) protein family as KCTD-12 or 12b also lead 
the receptor to desensitization (Benke et al., 2012).  
 
4.3. GABA transporters  
 
GABA transporters (GATs) are electrogenic secondary active transport proteins that 
couple the cotranslocation of 3 Na+, 1 Cl- and one GABA molecule across the plasma 
membrane of neurons and glia (Willford et al., 2015). They regulate GABA concentration in 
synaptic and extrasynaptic regions modulating the GABAergic signaling.  
 
Four GATs with different nomenclature have been cloned from different species. While 
mouse GATs are named GAT-1, GAT-2, GAT-3 and GAT-4, rat and human are called GAT-1, 
BGT-1, GAT-2 and GAT-3 (Rowley et al., 2012). Besides GABA, BGT-1 also transports betaine, 
and GAT-2 and GAT-3 β-alanine and taurine (Liu et al., 1993). These transporters are composed 
of 12 TM domains with the N- and C-termini located intracellularly and a potent glycosylation 
sequence between TM helices III and IV (Kanner, 1994). 
 
The regional and cellular distribution of GATs differs within the brain. GAT-1 and GAT-3 
are restricted to the brain, while BGT-1 and GAT-2 are also found in peripheral tissues, mainly 




studied of the GATs and is expressed throughout the brain. Although it is primarily found on 
presynaptic GABAergic neurons, it is also localized in astrocytic processes in human and 
monkey cerebral cortices (Conti et al., 1998), and in OLs (Zhang et al., 2014; Fattorini et al., 
2017). GAT-3 is mainly expressed by glial cells, specifically on distal astrocytic processes that 
are in direct contact with GABAergic terminals however, its expression has also been reported 
in neurons (Durkin et al., 1995; Minelli et al., 1996). In the adult rat brain, GAT-2 is strongly 
expressed in the leptomeninges, choroid plexus and ependyma, while in neurons and 
astrocytes its expression is weak (Conti et al., 1999).  
 
GATs are able to bind GABA and remove it from the extracellular space but, under 
certain ionic conditions, they can operate in a reverse manner transporting GABA from the 
cytoplasm back to the extracellular space, as observed in Bergmann glia (Barakat and Bordey, 
2002) and neurons (Wu et al., 2003) (Figure 12). GAT-1 transporter can be selectively blocked 
with anticonvulsant drugs as tiagabine or NNC-711 (Nielsen et al., 1991; Suzdak et al., 1992). 
Blocking GABA transport produces an increase in GABA levels in the synaptic cleft, which 
alleviates pathologies where GABA transmission is reduced. Thus, tiagabine is used as an add-












4.4. GABA receptors and transporters in oligodendrocytes 
 
Apart from neurons, OPCs also express functional GABAARs (Hoppe and Kettenman, 
1989; Von Blankenfeld et al., 1991; Kirchhoff and Kettenman, 1992; Borges et al., 1995; 
Williamson et al., 1998; Lin and Bergles, 2004; Cahoy et al., 2008) however, this expression 
decreases when they differentiate into OLs (Von Blankefeld et at., 1991; Vélez-Fort et al., 
2012) and it is lost when OLs are cultured in isolation needing the presence of axons to be 
Figure 12.  Ion/substrate coupling stochiometry of GABA transporters. A) Forward and B) reverse 







maintained (Arellano et al., 2016). This means that GABAAR expression in cultured OLs is 
driven by axonal cues (Arellano et al, 2016). Expression of GABABRs has also been reported in 
developing OLs (Luyt et al., 2007). On the other hand, colocalization studies between GAT-1 
GABA transporter and specific markers for OLs showed that GAT-1 is expressed in both 
immature and mature OLs in subcortical white matter, and in vitro functional assays 
demonstrated that OLs exhibit GAT-1 dependent GABA uptake (Fattorini et al., 2017). These 
data suggest a specific role for GABA signaling in oligodendroglial lineage development that 
could be relevant at the initial stages of myelination and/or during axon recognition (Vélez-
Fort et al., 2012; Zonouzi et al., 2015). Moreover, a recent study from Hamilton et al. (2017), 
points at GABA as a potential modulator of oligodendroglial cell number and myelination, and 
GABABRs has been involved in Schwann cell differentiation (Procacci et al., 2013). 
Understanding whether GABA and GABARs are relevant for myelination during development 
and remyelination in pathological conditions is crucial in the context of demyelinating diseases 
such as MS, in which reduced GABA levels and dysfunctional GABAergic transmission are 

















































































Demyelination is the main pathological hallmark in multiple sclerosis (MS) but pre-
existing oligodendrocytes (OLs) do not contribute to myelin restoration (Lassmann and Bradl, 
2017). Oligodendrocyte precursor cells (OPCs) are the primary source of remyelination after a 
demyelinating insult since these cells are able to proliferate, migrate into the lesion and 
differentiate into myelinating OLs (Franklin and ffrench-Constant, 2017). Differentiation of 
OPCs into mature myelinating OLs is a complex process mediated by neuron-glia interactions 
that involves the participation of a wide range of molecules such as growth factors and 
neurotransmitters like GABA (Zonouzi et al., 2015; Hamilton et al., 2017). We previously 
reported that the expression and function of GABAA receptors (GABAARs) in cultured OLs are 
regulated by axon-to glia interactions (Arellano et al., 2016), suggesting that GABAAR 
regulation in these cells is driven by axonal cues. Based on that, we hypothesize that GABA 
signaling may play a relevant role in OL differentiation and myelination and/or during axon-glia 
recognition. 
 
The general objective of this Doctoral Thesis has been to study the involvement of the 
GABAergic system in OPC differentiation as well as in OL myelination and remyelination after 
demyelinating insults using both in vitro and in vivo approaches. 
 
For this purpose, we defined the following specific objectives: 
 
1. To study the expression of the major components of the GABAergic system in OLs. 
 
2. To determine the contribution of GABARs to OL differentiation and myelination 
capacity in vitro. 
 
3. To evaluate the involvement of GABARs in myelination during development and in 
myelin restoration after experimental demyelinating lesions in vitro. 
 
4. To analyze the role of GABARs in myelination during development and in 

































All procedures with animals were carried out with the approval of the internal Animal 
Ethics Committee of the University of the Basque Country (UPV/EHU) and following the 
European Communities Council Directive.  In particular, all protocols were approved by the 
“Ethics Committee on Animal Experimentation” (CEEA) which is a collegiate authority in the 
operational structure of the Ethics Commission for Research and Teaching (CEID) of the 
University of the Basque Country. Animals were housed in standard conditions with 12 hours 
light cycle and with ad libitum access to food and water. All possible efforts were made to 
reduce the number of animals used in this study and their suffering. 
 
Experiments were performed in Sprague Dawley rats; C57BL/6 mice; transgenic mice 
expressing EYFP under the control of the NG2 promoter (NG2-EYFP; Karram et al., 2008), a 
generous gift from Dr. S. Mato (University of the Basque Country, UPV/EHU, Spain) and Dr. J. 
Trotter (Gutenberg University Mainz, Germany); and transgenic mice expressing fluorescence 
reporter DsRed under the control of the glial-specific proteolipid protein promoter (PLP-DsRed; 
Hirrlinger et al., 2005), generously provided by Dr. F. Kirchhoff (University of Saarland, 
Homburg, Germany). 
 
2. IN VITRO MODELS 
 
2.1. Rat cortical oligodendrocyte primary culture 
 
Purified OPCs were prepared from mixed glial cultures obtained from the forebrain of  
newborn (P0-P2) Sprague-Dawley rats according to the protocol of McCarthy and de Vellis, 
1980 with modifications (Chen et al., 2007; Canedo-Antelo et al., 2018; Sánchez-Gómez et al., 
2018). Briefly, forebrains were removed from the skulls, and after careful removal of the 
meninges, cortices were isolated and digested by incubation (15 min, 37°C) in Hank’s balanced 
salt solution (HBSS, without Ca2+ and Mg2+) containing 0.25% trypsin and 0.004% 
deoxyribonuclease (DNAse) (all from Sigma-Aldrich). Then, enzymatic reaction was stopped by 
adding Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 10% fetal bovine 
serum (FBS, Hyclone; both from Gibco) and the cell suspension was centrifuged at 1000 rpm 
for 5 min. The pellet was resuspended in 1 ml of the same solution and cells were dissociated 
by passage through needles (21G and 23G), centrifuged and resuspended again in IMDM + 
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10% FBS. Afterwards, cells were seeded into 75 cm2 flasks coated with poly-D-lysine (PDL; 1 
μg/ml; Sigma-Aldrich) and maintained in culture at 37°C and 5% CO2 with a medium change 
every 3 days. After 7 days in culture, flasks were shaken (400 rpm, 1 h, at 37°C) to remove 
adherent microglia. The remaining OPCs present on top of the confluent monolayer of 
astrocytes were detached by shaking overnight at 400 rpm. The resulting cell suspension was 
filtered through a 10 μm pore size nylon mesh and preplated in 100 mm coated Petri dishes 
(ThermoFisher Scientific) for 30 min at 37°C and 5% CO2, allowing microglia become firmly 
attached while OPCs were loosely attached and could be collected with a gentle shaking of the 
Petri dishes. The collected forebrain OPC cell suspension was filtered again through a 10 μm 
pore size nylon mesh. Cell number was determined by trypan blue staining (Sigma-Aldrich) 
with 20 μl of sample and the rest of the cell suspension was centrifuged at 1000 rpm for 10 
min and resuspended in a chemically defined medium (OL differentiation medium) consisting 
of a supplemented (4.5 g/l glucose and 0.11 g/l sodium piruvate) DMEM base with several 
factors that favor oligodendrocyte survival and development (Table 1).  
 
Table 1. Composition of oligodendrocyte differentiation medium. 
 
Reagent Concentration Company 
DMEM Base medium Gibco 
Insulin 5 μg/ml Sigma-Aldrich 
Penicillin/streptomycin 100 U/ml Lonza 
Bovine serum albumin (BSA) 100 μg/ml Sigma-Aldrich 
N-acetyl-cysteine 63 μg/ml Sigma-Aldrich 
L-glutamine 2 mM Sigma-Aldrich 
Transferrin 100 μg/ml Sigma-Aldrich 
Progesterone 62.5 ng/ml Sigma-Aldrich 
Sodium selenite 40 ng/ml Sigma-Aldrich 
Putrescine 16 μg/ml Sigma-Aldrich 
Triiodothyronine (T3) 30 ng/ml Sigma-Aldrich 
Thyroxine (T4) 40 ng/ml Sigma-Aldrich 
Ciliary neurotrophic factor (CNTF) 10 ng/ml Peprotech 
Neurotrophin 3 (NT3) 1 ng/ml Peprotech 
 
Cells were plated onto PDL-coated 14-mm-diameter coverslips in 24-well plates at 
densities between 4 x 103 and 8 x 104 cells per well and maintained at 37ºC and 5% CO2 in 





chemically defined OL differentiation medium. The purity of oligodendroglial cultures was 
confirmed by immunostaining with cell type-specific antibodies. After 1 day in culture, 
PDGFRα+ OPCs represented 97 ± 5% of the total cells, and after 3 days in OL differentiation 
medium, at least 98% were MBP+ cells (Sánchez-Gómez et al., 2018). 
 
2.2. Rat optic nerve-derived oligodendrocyte primary culture 
 
Primary cultures of optic nerve OLs were prepared from 11-day-old Sprague-Dawley 
rats as previously described (Barres et al., 1992) with modifications (Sánchez-Gómez et al., 
2018). Optic nerves were extracted and meninges were removed in supplemented (2 μl/ml 
gentamicin, 1 mg/ml BSA and 2 mM glutamine) HBSS under the microscope. After that, optic 
nerves were cut in small pieces and digested with 1.25 mg/ml collagenase, 0.125% trypsin and 
0.004% DNAse (all from Sigma-Aldrich) for 40 min at 37ºC. Then, enzymatic reaction was 
stopped by adding 10% FBS in DMEM, and cell suspension was centrifuged at 1000 rpm for 5 
min. The pellet was resuspended in 1 ml of the same solution. Mechanical dissociation was 
performed by passage through needles (23, 25 and 27G), and the resulting cell suspension was 
filtered through a 40 μm nylon mesh (Millipore). Cell number was determined by trypan blue 
staining with 10 μl of sample and the rest of the cell suspension was centrifuged at 1000 rpm 
for 10 min. The obtained pellet was resuspended in the chemically defined medium described 
before (OL differentiation medium, Table 1). Cells were seeded onto PDL-coated 14-mm-
diameter coverslips in 24 well plates at a density of 5 x 103 cells per well. Cells were 
maintained at 37°C and 5% CO2 in OL differentiation medium. After 3-5 days in vitro (DIV), 
cultures were constituted of at least 98% cells positive for O4 antigen and myelin basic protein 
(O4+/MBP+). The majority of the remaining cells were positive for the glial fibrillary acidic 
protein (GFAP) immunostaining. No A2B5+ cells or microglial cells were identified in these 
cultures (Alberdi et al, 2002). 
 
2.3. Dorsal root ganglion neurons-oligodendrocyte precursor cells coculture 
 
Dorsal root ganglion (DRG) neurons were obtained from E15 rat embryos as previously 
described (Arellano et al., 2016). The dissociated cells were resuspended in DRG medium 
composed of Neurobasal medium (Gibco) supplemented with 10% FBS (Sigma-Aldrich), 50 
ng/ml nerve growth factor (NGF; ThermoFisher Scientific) and 2% B27 supplement (Gibco). 
Cells were plated onto PDL-laminin coated coverslips at a density of 5 x 104 cells per coverslip. 
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DRG neurons were cultured for at least 2 weeks in DRG medium alone with fresh medium 
added every 3 days.  
 
Isolated OLs (either from optic nerve or cortex) prepared as mentioned before were 
seeded onto a 2- to 3-week-old DRG neuron culture at a density of 2 x 104 cells/coverslip. The 
medium was changed to a 50:50 mixture of OL differentiation medium and DRG medium, 
without NGF, and cocultures were left for 14-21 days in control conditions or in presence of 10 
μM or 50 μM GABA.  
 
2.4. Cerebellar organotypic culture  
 
Cultures were elaborated from cerebella of P5-P7 or P11-day-old Sprague Dawley rats 
and P11-day-old transgenic PLP-DsRed mice according to previously described procedures 
(Dusart et al., 1997; Doussau et al., 2017; Tan et al., 2018). Briefly, after decapitation cerebella 
were dissected out and cut with a tissue chopper (Mcllwain) into 350 μm parasagittal slices. 
Meninges were removed and slices were plated onto 0.4 μm pore size Millicell CM culture 
inserts (Millipore), containing 2-3 slices each. Rat cerebellar slices were maintained in 6-well 
plates for 13-15 days and mice cerebellar slices for 11 days in culture medium consisting of 
50% basal medium with Earle’s salt (BME), 25% HBSS, 25% inactivated horse serum (all from 
Gibco), 5 mg/ml glucose (Panreac), 2 mM L-glutamine (Sigma-Aldrich) and antibiotic-
antimycotic solution (100 U/ml of penicillin, 100 μg/ml of streptomycin and 0.25 μg/ml of 
amphotericin B; ThermoFisher Scientific) at 37°C in a humidified atmosphere with 5% CO2. 
Culture medium was replaced every 2-3 days. 
 
2.4.1. EdU labeling and detection 
 
5-ethynyl-2´-deoxyuridine (EdU; Invitrogen) is a thymidine analogue that is 
incorporated into the DNA of the cells as they undergo DNA replication (Chehrehasa et al., 
2009). EdU (10 μM) was added to the organotypic medium on DIV6 for 48 h, to quantify the 
number of dividing cells between days 6 and 8 in vitro. EdU labeling was performed using Click-









2.4.2. LPC-induced demyelination in cerebellar slices 
 
LPC-induced demyelination experiments were carried out in cerebellar slices from P11 
rats and P11 transgenic PLP-DsRed (Birgbauer et al., 2004). Slices were maintained for 7 days 
in vitro and incubated for 16 h with 0.5 mg/ml LPC (Sigma-Aldrich). After that, slices were 
rinsed with culture medium for 10 min and then fresh medium was added. Treatments with 
GABAergic drugs were performed at the same time or just after LPC-stimulus. Slices were fixed 
in culture inserts or proteins were extracted 4-6 days after treatment. 
 
2.5. Optic nerve-derived organotypic culture 
 
Cultures were obtained from optic nerves from P11-day-old transgenic PLP-DsRed 
mice. Optic nerves together with the retina were extracted in order to maintain tissue 
organization and cellular connections. Meninges and residual tissue were removed in 
supplemented (2 μl/ml gentamicin, 1 mg/ml BSA and 2 mM glutamine) HBSS under the 
microscope, and the optic nerve-retina units were maintained in 0.4 μm pore size Millicell CM 
culture inserts (Millipore), containing one unit each. Explants were maintained in 6-well plates 
for 3 days in culture medium described before for cerebellar organotypic cultures at 37°C in a 
humidified atmosphere with 5% CO2. To favor appropriate feeding of the optic nerve-retina 
unit, 50 μl of culture medium were added directly over the tissue (Azim and Butt, 2011). At the 
end of culture period, explants were fixed with 4% paraformaldehyde (PFA) in 0.1 M 
phosphate-buffered saline (PBS) for 30 min at room temperature (RT), washed three times in 
0.1 M PBS, taken out from the culture inserts and mounted on glass slides with fluorescent 
mounting medium (Prolong gold antifade reagent).  
 
3. IN VIVO MODELS 
 
3.1. Developing Sprague-Dawley rats  
 
P6-day-old Sprague Dawley rat pups were daily intraperitoneally (i.p) injected with 
vehicle or baclofen (4 mg/kg; Tocris) for 6 or 16 days and processed for immunohistochemistry 
and electrophysiology. Drugs were diluted in saline solution (0.9% NaCl; Panreac). The volume 
of injection was 4 ml/kg. 
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3.2. LPC-induced demyelination in C57BL/6 mice  
 
LPC-induced demyelination was carried out in the spinal cord of 10-week-old female 
C57BL/6 mice as previously described (Tepavcevic et al., 2014). Briefly, demyelinating lesions 
were induced by a stereotaxic injection of 0.5 μl of 1% LPC in sterile saline solution. Before the 
surgery, anesthesia was induced by intraperitoneal injection of a solution of ketamine (100 
mg/kg; Fatro)/ xylazine (10 mg/kg; Calier). Two longitudinal incisions into longissimus dorsi at 
each side of the vertebral column were performed, and the muscle tissue covering the column 
was removed. Animals were placed in a stereotaxic frame, the 13th thoracic vertebra was fixed 
between bars specifically designed for mouse spinal cord surgery, and intravertebral space was 
exposed by removing the connective tissue. Dura mater was pierced with a 30G needle, and 
LPC was injected via Hamilton syringe attached to glass micropipette using a stereotaxic 
micromanipulator. The lesion site was marked with sterile charcoal (Sigma-Aldrich) so that the 
area of tissue at the lesion center could be unambiguously identified. Following LPC injection, 
the wound was sutured and the animals were allowed to recover. Buprenorphine (0.1 mg/kg; 
Dechra) was subcutaneously administered as postoperative analgesic treatment. Five days 
after surgery, mice were daily i.p injected with vehicle (saline solution) or baclofen (8 mg/kg) 
for 7 days and processed for immunohistochemistry at the peak of oligodendrocyte 




The following substances were used: GABA (Ref. A2129), gabazine (Ref. SR-95531) 
both from Sigma-Aldrich); baclofen (Ref. 0796), CGP55845 (Ref. 1248), muscimol (Ref. 0289) all 




5.1. Cultured oligodendrocytes 
 
Cells on the coverslips were fixed with 4% PFA in 0.1 M PBS for 20 min at RT and rinsed 
three times with PBS. Then, fixed cells were permeabilized with 0.1% Triton X-100 (Sigma-
Aldrich), blocked with 4% goat serum (Palex) in 0.1 M PBS for 1 h at RT and incubated with 
primary antibodies (Table 2) overnight at 4ºC in the same solution. After incubation, cells were 





washed in PBS and incubated with fluorochrome-conjugated antibodies (Table 3) diluted in 
PBS with 4% goat serum for 1 h at RT. Incubation for 5 min with DAPI (4 μg/ml; Sigma-Aldrich) 
was used to identify cell nuclei. Cells were washed three times in PBS and mounted on glass 
slides with fluorescent mounting medium (Prolong gold antifade reagent; ThermoFisher 
Scientific). 
 
Table 2. Primary antibodies used for immunocytochemistry. 
 
Antibody Host Dilution Company 
anti-Olig2 mouse 1:1000 Millipore 
anti-Olig2 rabbit 1:800 Millipore 
anti-PDGFRα rabbit 1:200 Santa Cruz 
anti-NG2 rabbit 1:200 Millipore 
anti-MBP mouse 1:500 Biolegend 
anti-PLP rabbit 1:100 Abcam 
anti-GABARB1 rabbit 1:50 Alomone 
anti-GABARB2 rabbit 1:50 Alomone 
anti-GAT1 guinea pig 1:100 Synaptic Systems 
anti-GAT3 rabbit 1:100 Alomone 
anti-GAD65/67 mouse 1:250 Santa Cruz 
anti-MAOB rabbit 1:100 Sigma-Aldrich 
anti-Ki67 rabbit 1:500 Vector 
anti-GABA mouse 1:7000 Matute and Streit, 1986 
anti-A2B5 IgM mouse 1:10 
kindly supplied by Dr. Paola 
Bovolenta (CBMSO, Madrid) 
O4 IgM antigen mouse 1:40 
kindly supplied by Dr. Christine 
Thomson (University of Glasgow) 
anti-MBP mouse 1:100 Covance 
anti_NF-L rabbit 1:200 Cell Signaling 
 
For GABA immunostaining, cells were fixed with 4% PFA and 0.1% glutaraldehyde in 
0.1 M PBS for 20 min at RT, permeabilized and blocked as described before and incubated with 
primary antibody (Table 2; Matute and Streit, 1986). Specificity of the primary antibody was 
checked by doing antibody absorption. For that, primary antibody was incubated overnight at 
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4ºC in blocking solution plus GABA 10 mM. Then, the mix was centrifuged for 5 min at 5000 
rmp at 4ºC and supernatant was used for immunocitochemistry. 
 
For immunostaining of A2B5 or the O4 antigen, live cells were incubated for 1 h or 30 
min respectively at 37°C with primary antibodies (Table 2) in OL differentiation medium. Then, 
cells were rinsed with 0.1 M PBS, fixed with 4% PFA in PBS as described before, and incubated 
for 1 h at RT with secondary antibodies (Table 3) diluted in PBS containing 4% goat serum. 
After being rinsed, coverslips were mounted on glass slides. 
 
Table 3. Secondary antibodies used for immunocytochemistry. 
 
Antibody Host Dilution Company 
IgG mouse Alexa Fluor 488 goat 1:400 Invitrogen 
IgG mouse Alexa Fluor 594 goat 1:400 Invitrogen 
IgG rabbit Alexa Fluor 488 goat 1:400 Invitrogen 
IgG rabbit Alexa Fluor 594 goat 1:400 Invitrogen 
IgG guinea pig Alexa Fluor 647 donkey 1:400 Jackson Labs 
IgM mouse Alexa Fluor 488 goat 1:200 Invitrogen 
IgM mouse Texas Red Conj. goat 1:200 Calbiochem 
 
5.2. DRG neurons-OPCs coculture  
 
Cultures were fixed with 4% PFA in PBS as described before, permeabilized with 0.1% 
Tween 20 and blocked with 5% goat serum in PBS for 30 min at RT. After that, cells were 
incubated overnight at 4ºC in blocking solution with the primary antibodies mouse anti-MBP, 
to visualize myelin expression, and rabbit anti-neurofilament-L (NF-L; Table 2) to visualize 
neurites. Then, cells were rinsed and incubated for 2 h at RT with Alexa Fluor 488-conjugated 
anti-mouse IgG (H+L) and Alexa Fluor 594-conjugated anti-rabbit IgG (H+L) (1:200; Molecular 
Probes).  
 
5.3. Cerebellar organotypic slices and brain sections  
 
Cerebellar slices in culture inserts were fixed with 4% PFA in 0.1 M PBS for 40 min at 
RT. After 3 washes in 0.1 M PBS, slices were taken out from the culture inserts and kept in 0.1 
M PBS with 0.02% sodium azide (Sigma-Aldrich) at 4ºC. Sprague-Dawley rats and transgenic 





mice were anesthetized with 6% chloral hydrate (Panreac) in 0.1 M PBS and transcardially 
perfused with 4% PFA in 0.1 M phosphate buffer (PB). Brains were extracted and postfixed 
with the same solution for 3 h at RT, placed in 0.1 M PBS with 0.02% sodium azide at 4ºC and 
maintain at -20ºC in cryoprotectant solution (30% ethylene glycol (Sigma-Aldrich), 30% glycerol 
(Merck) and 10% PB 0.4 M in dH2O). Tissue was cut using a Microm HM650V vibrating blade 
microtome to obtain coronal 40 μm-thick sections.  Cerebellar slices or free-floating vibratome 
sections were permeabilized with 0.1% Triton X-100 and blocked with 4% goat serum with 
gentle shaking for 1 h at RT. Then, slices were incubated with primary antibodies (Table 4) in 
blocking solution with 4 or 1% goat serum respectively, overnight at 4ºC with gently shaking. 
After three washes in 0.1 M PBS, with or without 0.1% Triton X-100 respectively, slices were 
incubated in the same solution as primary antibodies, containing fluorochrome-conjugated 
secondary antibodies (1:200-1:500; Table 5) and DAPI (4 μg/ml) for 1 h at RT with gently 
shaking. After that, slices were washed three times in 0.1 M PBS with or without 0.1% Triton X-
100 respectively, and mounted on glass slides with fluorescent mounting medium (Prolong 
gold antifade reagent).  
 
5.4. Mice spinal cord tissue samples 
 
LPC-injected mice were anesthetized with 6% chloral hydrate and transcardially 
perfused with 2% PFA in 0.1 M PB for 20 min. Spinal cords were extracted, additionally post-
fixed with the same solution for 30 min at RT, and cryoprotected in 15% sucrose (Panreac) for 
48-72 h. Then, tissue samples were embedded in 7% gelatin (Sigma-Aldrich)/ 15% sucrose 
solution and frozen in isopentane (Honeywell) for 2 min before cryostat cutting. Samples were 
cut using a cryostat CM3050 S (Leica) at 12 μm. 
 
Spinal cord sections were left at RT for an 1 h, rehydrated in Tris buffer saline (TBS; 20 
mM Tris and 1.4 M NaCl in dH2O, pH 7.6) for 30 min, incubated with absolute ethanol (Sharlab) 
for 15 min at -20ºC, and blocked and permeabilized with 1% BSA (ThermoFisher Scientific), 5% 
goat serum and 0.1% Triton X-100 for 30 min at RT. Then, slices were incubated with primary 
antibodies (Table 4) in blocking solution overnight at 4ºC. After three washes in TBS, slices 
were incubated for 1 h at RT in the same solution as primary antibodies, containing 
fluorochrome-conjugated secondary antibodies (1:500; Table 5). 
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Table 4. Primary antibodies used for immunohistochemistry. 
 
Antibody Host Dilution Company 
anti-GABARB1 rabbit 1:200 Alomone 
anti-GABARB2 rabbit 1:200 Alomone 
anti-GAT1 guinea pig 1:500 Synaptic Systems 
anti-GAT3 rabbit 1:100 Alomone 
anti-APC (CC1) mouse 1:200 Calbiochem 
anti-Olig2 mouse 1:200-1:1000 Millipore 
anti-Olig2 rabbit 1:500-1:1000 Millipore 
anti-MBP mouse 1:1000 Biolegend 
anti-MBP rabbit 1:200 Millipore 
anti-MBP chicken 1:200 Millipore 
anti-neurofilament-L rabbit 1:1000 Cell Signaling 
anti-Ki67 rabbit 1:200 Vector 
anti-PDGFRα rat 1:300 BD Biosciences 
anti-Iba1 guinea pig 1:200 Synaptic systems 
 
Then, slices were washed three times in TBS, incubated with DAPI for 5 min and 
washed three times in TBS again. Slices were washed rapidly with Mili-Q H2O before mounting 
on glass slides with Fluoromount-G mounting medium (SouthernBiotech).  
 
For APC and Olig2 immunostainning, antigen retrieval was performed by heating the 

















Table 5. Secondary antibodies used for immunohistochemistry. 
 
Antibody Host Company 
IgG rabbit Alexa Fluor 488 goat Invitrogen 
IgG rabbit Alexa Fluor 594 goat Invitrogen 
IgG mouse Alexa Fluor 488 goat Invitrogen 
IgG mouse Alexa Fluor 594 goat Invitrogen 
IgG2b mouse Alexa Fluor 488 goat Invitrogen 
IgG2b mouse Alexa Fluor 594 goat Invitrogen 
IgG2a mouse Alexa Fluor 546 goat Invitrogen 
IgG chicken Alexa Fluor 647 goat Invitrogen 
IgG rat Alexa Fluor 488 goat Invitrogen 
IgG guinea pig Alexa Fluor 594  goat Invitrogen 
IgG guinea pig Alexa Fluor 488 goat Invitrogen 
 
5.5. Image acquisition and analysis  
 
Images were acquired using a Zeiss Axioplan2 fluorescence microscope (Department of 
Neurosciences, UPV/EHU), an Olympus Fluoview FV500 (Analytical and High-Resolution 
Microscopy Service in Biomedicine, UPV/EHU), a Leica TCS STED SP8 laser scanning confocal 
microscope and 3DHISTECH panoramic MIDI II digital slide scanner (Achucarro Basque Center 
for Neuroscience). Same settings were kept for all samples within one experimental group.  
 
Data quantification on isolated OPCs/OLs was performed as follows: NG2+, A2B5+ and 
Ki67+ cells were counted from at least 10 fields per coverslip in images acquired by using a 20x 
objective in a Zeiss Axioplan2 fluorescence microscope. MBP+ cells and values of MBP+ cells 
occupied area were derived from at least 15 fields per coverslip using a 20x objective. All these 
quantifications were obtained by using ImageJ software (NIH, Bethesda, MD). Morphology of 
MBP+ cells was analyzed by using a concentric circles macro (created by Jorge Valero, 
Achucarro Basque Center for Neuroscience, Spain). Concentric circles at 10 μm intervals 
emerging from the center of the cell nucleus were created and MBP protein fluorescence 
signal was quantified after background subtraction. Data were represented as percentage of 
MBP in soma or periphery respect to MBP total signal for each cell analyzed. All quantifications 
were performed on a minimum of 2 coverslips per treatment of at least 3 independent 
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experiments. To avoid the effects of the variations observed in basal differentiation between 
trials, all experimental conditions were paired with internal control performed in parallel and 
derived from common pools of cells. 
 
For DRG neurons-OPCs cocultures, MBP expression was analyzed by using ImageJ 
software in 20 random fields per coverslip in images captured with a 20x objective in an 
Olympus Fluoview FV500. The number of MBP+/NF-L+ segments was counted on a minimum of 
30 random fields per coverslip at 40x magnification. All data were showed as percentage 
respect to non-treated cocultures. 
 
Images from cerebellar organotypic slices of P5-P7 rats, optic nerve explants of PLP-
DsRed transgenic mice and cerebellar organotypic slices of PLP-DsRed transgenic mice were 
acquired by using a 20x objective in a Leica TCS SP8 laser scanning confocal microscope. Cells 
from rat cerebellar slices were counted blindly along the z-stack. At least three different fields 
from two slices per experiment were analysed by using LAS AF Lite software (Leica). The 
fluorescence signal corresponding to the PLP-DsRed OLs was quantified by ImageJ software 
and the data were expressed as arbitrary units of fluorescence for each experimental situation. 
Three independent experiments were included in the analyses. All images shown are 
projections from z-stacks. 
 
Images of cerebellar organotypic slices of P11 rats and rat brain slices were acquired 
using a 20x objective (0.8 NA) in a 3DHISTECH panoramic MIDI II digital slide scanner and using 
a 63x in a Leica TCS STED SP8 laser scanning confocal microscope. Fiber remyelination index 
was obtained by using ImageJ software as Manders´ overlap coefficient of MBP over NF-L 
staining of at least three different areas from no less than three independent experiments. Cell 
number from the corpus callosum of the brain sections were quantified by using ImageJ 
software. A minimum of 3 different sections per animal were counted from at least 3 rats. 
 
Images of LPC-injected mice spinal cord sections were collected using a 40x objective 
(1.3 NA) and a 63x objective (1.4 NA) in a Leica TCS SP8 laser scanning confocal microscope and 
imported to ImageJ software. The area lacking MBP staining within the dorsal funiculus of the 
spinal cord (area of demyelination) was delimited as region of interest (ROI) and measured. 
Cells positive for the markers of interest were counted from at least 3 different slices per 
animal of as a minimum of 3 mice. Results are presented as total number of positive cells per 
lesion area measured. 





6. PROTEIN EXTRACTS PREPARATION AND DETECTION BY WESTERN BLOTTING 
 
6.1. Oligodendrocyte protein preparation 
 
Cultured cortical OLs were washed twice in cold 0.1 M PBS and scraped in 60 μl of 
sample buffer (62.5 mM Tris pH 6.8, 10% glycerol, 2% SDS, 0.002% bromophenol blue and 
5.7% β-mercaptoethanol in dH2O) per treatment (2 wells and 8 x 10
4 cells per well). All the 
process was performed on ice to avoid protein degradation. After that, lysates were boiled at 
99ºC for 8 min. 
 
6.2. Cerebellar slice protein preparation 
 
After 2 days in culture, cerebellar slices from P5-P7-day-old rats were treated with 
GABAergic drugs for 13 days. Slices from P11-day-old rats were treated as previously 
described. After treatment, each slice was resuspended in 80 μl of sample buffer and then 
boiled at 99ºC for 8 min. 
 
6.3. Western blotting 
 
Protein samples were size-separated by SDS-PAGE in 12% Tris-Glycine polyacrylamide 
gels and Tris-Glycine polyacrylamide gels for the separation of polypeptides from 10-200 kDa 
(Bio-Rad). Electrophoresis was conducted in a Tris-Glycine buffer (25 mM Tris, 192 mM glycine, 
0.1% SDS in dH2O, pH 8.3) by using the Criterion cell system (Bio-Rad). Gels were transferred to 
PVDF membranes by using Trans-Blot® TurboTM Transfer System (Bio-Rad).  
 
Membranes were blocked for 90 min at RT in blocking solution consisting of Tris buffer 
saline tween-20 (20 mM Tris, 1.4 M NaCl, 0.05 % Tween-20 in dH2O, pH 7.6) supplemented 
with either 5% BSA (Sigma-Aldrich) or 5% Phosphoblocker blocking reagent for phosphorylated 
protein detection. Then, they were incubated with specific primary antibodies (Table 6) in the 
same solution overnight at 4ºC with gentle shaking. After that, membranes were washed three 
times in TBS-T and incubated with horseradish peroxidase-conjugated secondary antibodies 
(1:2000; Sigma-Aldrich) in blocking solution for 90 min at RT. 
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Immunoreactive proteins were detected by using enhanced electrochemical 
luminescence (Supersignal West Dura or Femto; ThermoFisher Scientific) and images were 
acquired with a ChemiDoc XRS Imaging System (Bio-Rad). Protein bands were quantified by 
volumetry using ImageLab software (version 3.0; Bio-Rad) and were normalized with loading 
control. At least three independent experiments were analyzed in each case. 
 
Antibodies for phosphorylated proteins were stripped using Restore Western Blot 
stripping buffer (ThermoFisher Scientific) for 15 min at RT with shaking. Membranes were then 
washed three times in TBS-T, blocked in 5% BSA and incubated with other primary antibodies. 
 
Table 6. Antibodies for Western blotting. 
 
Antibody Host Dilution Company 
anti-PDGFRα rabbit 1:1000 Santa Cruz 
anti-GABARB1 mouse 1:500 Abcam 
anti-GABARB2 rabbit 1:200 Alomone 
anti-GAT3 rabbit 1:500 Alomone 
anti-GAD65/67 mouse 1:500 Santa Cruz 
anti-MAOB rabbit 1:500 Sigma-Aldrich 
anti-MAG mouse 1:500 Santa Cruz 
anti-CNPase mouse 1:1000 Sigma-Aldrich 
anti-MBP mouse 1:1000 Biolegend 
anti-phospho-Src [Tyr418]     rabbit      1:1000 ThermoFisher Scientific 
anti-phospho-CREB (Ser133) rabbit 1:1000 Cell signaling 
anti- Src [36D10] rabbit      1:1000 Cell Signaling 
anti-CREB rabbit 1:1000 Cell Signaling 
anti- GAPDH mouse      1:1000 Millipore 
anti-β-tubulin mouse 1:5000 Abcam 
anti-β-actin rabbit 1:2000 Sigma-Aldrich 
 
 





7. RNA EXTRACTION AND QUANTIFICATION 
 
7.1. RNA isolation 
 
Total RNA was extracted from cultured cortical OLs with Trizol reagent (ThermoFisher 
Scientific) according to the manufacturer´s recommendations (Invitrogen). RNA concentration 
and integrity were measured by a spectrophotometer Nano DropTM 2000 (ThermoFisher 
Scientific). 
 
7.2. Retrotranscription and Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) 
 
Strand cDNA synthesis was performed in a 20 μl reaction with 5x buffer (Invitrogen), 
0.1 M DTT, random primers (Promega), dNTPs (Invitrogen), RNAase OUT and SuperScriptTM III 
reverse transcriptase (Invitrogen) following manufacturer´s instructions in a Veriti Thermal 
Cycler (Applied Biosystems). Resulting cDNA samples were diluted in sterile Mili-Q H2O. 
 
Real-time quantitative PCR (qPCR) reactions were performed by triplicates in 2.95 μl 
RNAse-free water (Promega), 5.2 μl SYBR-Green (Bio-Rad), 1.35 μl properly diluted primers and 
0.5 μl cDNA sample using a Bio-Rad CFX96TM Real-time PCR Detection System. Amplification 
reactions were optimized (3 min at 95ºC, 40 cycles of 10 sec at 95ºC and 30 sec at 60ºC). 
Specific primers for GABAB1 and GABAB2 were obtained from ThermoFisher Scientific and 
primers for GAPDH and cyclophilin A (CicA) were designed using Primer Express (Applied 
Biosystems) and PrimerBlast (NIH) (Table 7). PCR product specificity was checked by melting 
curves. Data were normalized to GAPDH and CicA housekeeping genes using a normalization 
factor obtained in geNorm software. 
 
Table 7. Primers used to analyze GABAB1 and GABAB2 gene expression. 
 
Gene Forward primer secquence Reverse primer secquence 
Gabbr1 AGATTGTGGACCCCTTGCAC AGAAAATGCCAAGCCACGTA 
Gabbr2 CACCGAGTGTGACAATGCAAA CCAGATTCCAGCCTTGGAGG 
GAPDH GAAGGTCGGTGTCAACGGATTT CAATGTCCACTTTGTCACAAGAGA 
CicA CAAAGTTCCAAAGACAGCAGAAAA CCACCCTGGCACATGAATC 
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8. CELL VIABILITY ASSAY 
 
Culture OL viability was measured 24 and 72 h after treatment. Cells were incubated 
with 1 μM calcein-AM (ThermoFisher Scientific) for 30 min at 37ºC in OL differentiation 
medium and then washed twice in pre-warmed 0.1 M PBS. Emitted fluorescence was 
measured using a Synergy-HT fluorimeter (Bio-Tek) as indicated by the supplier (485 nm 
excitation wavelength and 528 nm emission wavelength). All experiments were performed in 
triplicate. The values provided are the averages of at least three independent experiments. 
 
9. ELECTROPHYSIOLOGY  
 
Compound action potentials (CAPs) were measured in the corpus callosum of P25-P42-
day-old Sprague Dawley rats treated with vehicle or baclofen (4 mg/kg/day). Animals were 
anesthetized with isofluorane (Zoetis) and brains were cut in 400 μm-thick coronal sections by 
using a Leica VT 1200S vibrating blade microtome (Leica Microsystems) at 4ºC in a cutting 
solution consisting of: 215 mM sucrose, 2.5 mM KCl, 26 mM NaHCO3, 1.6 mM NaH2PO4, 20 mM 
glucose (all from Panreac), 1 mM CaCl2 (Merck), 4 mM MgCl2, and 4 mM MgSO4 (both from 
Sigma-Aldrich).  After that, sections were incubated in a 1:1 mixture of cutting solution and low 
calcium artificial cerebrospinal fluid (aCSF) for 30 min at 32ºC. Then, sections were maintained 
in aCFS during the recordings (124 mM NaCl, 2.5 mM KCl, 10 mM glucose, 25 mM NaHCO3, 
1.25 mM NaH2PO4, 2.5 mM CaCl2, and 1.3 mM MgCl2). After that, evoked compound potentials 
(CAPs) were recorded with a pulled borosilicate glass pipette (≈ 1 MΩ resistance) filled with 
NaCl 3M by electrically stimulating corpus callosum with a bipolar electrode (CE2C55, FHC, 
USA), stimulation intensities ranging from 30 to 3000 μA (100 μs pulses, Master-8, AMPI, 
Israel). Conduction velocity values for myelinated (N0), partially myelinated (N1) and 
unmyelinated (N2) fibers were calculated as the slope of a straight line fitted through a plot of 
the distance between the recording and stimulating electrodes versus the response latency 
(time to N0, N1 or N2, respectively) in 4 different distances from both electrodes (500, 1000, 
1500 and 2000 μm) subtracting the baseline of the stimulus artifact. Latencies were calculated 









10. STATISTICAL ANALYSIS 
 
All data are presented as mean ± S.E.M. Statistical analysis were performed using 
GraphPad Prism statistical software (version 5.0; GraphPad software). Comparisons between 
multiple experimental groups were made using one-way analysis of variance (ANOVA) 
followed by Tukey’s post hoc test. For comparisons between a single experimental group and a 
control group, we used two-tailed paired or unpaired Student’s t-test assuming equal variance. 
In all instances, statistical differences were considered significant where p < 0.05. All the 
images shown represent the data obtained at least in three independent experiments. 
 
RESULTS 









Differentiation of OPCs into mature OLs is a key event for myelination during 
development and for adult remyelination in the context of demyelinating diseases such as MS 
(Franklin and Ffrench-Constant, 2017; Kremer et al., 2019). Failure of OPC differentiation into 
myelinating OLs or the inability of newly OLs to form new myelin sheaths lead to inefficient 
remyelination (Fancy et al., 2011). Thus, understanding the mechanisms that control 
oligodendroglial differentiation and myelination is essential for identifying therapeutic 
strategies that promote myelin repair and limit disability in MS. 
 
OL differentiation and myelination are complex processes mediated by neuron-glial 
interactions that require the participation of several regulators like neurotransmitters and 
growth factors. OPCs receive both glutamatergic and GABAergic synaptic inputs (Bergles et al., 
2000; Lin and Bergles, 2004; Karadottir et al., 2008; Fannon et al., 2015; Zonouzi et al., 2015), 
and oligodendroglial cells express a wide range of neurotransmitter receptors (Verkhratsky 
and Steinhaüser, 2000; Butt et al., 2014). This evidence suggests that these molecules are 
involved in the regulation of OL development and myelination, as it has been described for 
ATP, adenosine, glutamate or GABA (Domercq et al., 2010; Li et al., 2013; Fannon et al., 2015; 
Zonouzi et al., 2015; Hamilton et al., 2017).   
 
In the present study, we demonstrate that OLs are able to synthesize GABA and express the 
major components of the GABAergic system, including GABAARs, GABABRs, GAT-1 and GAT-3 
GABA-transporters as well as the two GABA-synthesizing enzymes, GAD65/67 and MAOB. 
Notably, we show that GABABR stimulation in vitro promotes OPC differentiation enhancing 
the production of myelin-related proteins. This process requires the phosphorylation of CREB 
and kinases from the Src family. Interestingly, exogenous GABA and the specific GABABR 
agonist baclofen regulate myelination in DRG-OPC cocultures by increasing MBP levels and 
myelin sheath segments around axons. In cerebellar organotypic slices, GABABR activation 
increases myelin protein levels and GABA signaling attenuates LPC-induced demyelination. 
Finally, we have observed that GABABR stimulation accelerates OL differentiation in vivo in 
LPC-induced demyelinating lesions in the adult mice spinal cord, as well as during development 
in the rat corpus callosum and cingulate cortex. In addition, conduction velocity of myelinated 
fibers in the rat corpus callosum increases in animals treated with baclofen. These results 




differentiation and myelination and point at these receptors as a possible therapeutic target to 
promote remyelination in the context of demyelinating diseases. 
 
1. Oligodendrocytes express the major components of the GABAergic system and 
synthesize GABA 
 
It is well known that oligodendroglial cells express GABAA receptors (Hope and 
Kettenmann, 1989; Von Blankenfeld et al., 1991; Berger et al., 1992; Cahoy et al., 2008) and, to 
a lesser extent, GABAB receptors (Luyt et al., 2007). However, previous studies have reported 
that GABAAR expression decreases as OPCs differentiate into OLs (Von Blankenfeld et at., 1991; 
Arellano et al., 2016) and is lost when these cells are cultured in isolation, needing the 
presence of axons to be maintained (Arellano et al., 2016). In this study, we provide evidence 
that this is not the case for GABABRs as its expression in OLs in vitro remains largely stable over 
time even in absence of axons. Moreover, we have found its presence in oligodendroglial cells 
from cerebellar organotypic slices, and in vivo GABABR expression occurs in both OPCs (NG2
+ 
cells) and in mature OLs (CC1+ and PLP+) in the juvenile rodent brain, persisting throughout 
adulthood (Serrano-Regal et al., 2019). We also found GABABRs in mature OLs from the mouse 
spinal cord. These observations are in contrast with that from Charles et al. (2003), who did 
not find colocalization between GABABRs and myelin forming oligodendrocytes in the white 
matter of rat spinal cord. Moreover, it has been reported a downregulation of GABABRs in 
mature OLs (Luyt et al., 2007) as well as in pre- and non-myelinating Schwann cells from the 
sciatic nerve (Corell et al., 2015) but the mechanisms that regulate GABABR expression are 
likely different between central and PNS. However, and in line with the findings reported in the 
current study, Corell et al. observed that GABA, via GABABRs, is a positive regulator of 
myelination without affecting Schwann cell proliferation. 
 
In this study, we demonstrate GABABR mRNA and protein expression in mature OLs 
cultured in isolation as well as in vivo in the juvenile and adult rodent CNS (Serrano-Regal et 
al., 2019). Nevertheless, the specific composition of GABABRs in OLs still needs to be 
determined in order to better understand their function in these glial cells. In this sense, while 
GABABR-mediated mechanisms in neurons have been well characterized, function of GABABRs 
in OLs is less well understood (Xu et al., 2014; Booker et al., 2018). In order to resolve this 
question, we developed electrophysiological recordings and calcium imaging assays on OLs 




described for other cells types. However, we could not get results that confirmed this coupling 
(data not shown). In this line, a recent paper describes that GABABRs are present on dendritic 
membranes of CA1 somatostatin interneurons, but do not activate the canonical Kir3 signaling 
cascade, while pyramidal neurons do it (Booker et al., 2018). Our data suggest that GABABRs in 
OLs may signal through alternative effectors, whose nature remains elusive. 
 
Regarding GABA transporters, Fattorini et al. (2017) described that OLs express a 
functional GAT-1 GABA transporter. Here we show that they also express GAT-3 GABA 
transporter and again, the expression of both transporters is stable over time as we have 
detected them at all stages of maturation in cultured OLs. Moreover, we demonstrate the 
presence of both transporters in mature OLs of the juvenile rat brain (Serrano-Regal et al., 
2019). The presence of GAT-1 and GAT-3 in these cells is not unexpected as GAT-1 may 
contribute to the effects of GABA on OLs by regulating GABA levels, either by taking up GABA 
or by releasing it, if operating in the reverse mode as described in neurons (Wu et al., 2003) 
and Bergmann glia (Barakat and Bordey, 2002). In turn, GAT-3 might cooperate with GAT-1 in 
the regulation of GABA homeostasis in OLs, however its precise contribution requires further 
investigation.   
 
GABA can be synthesized through two different pathways, either from glutamate 
decarboxylation by GAD65/67 enzyme, or alternatively, from putrescine by the action of MAOB 
(Angulo et al., 2008; Yoon et al., 2014). Consistent with databases (Zhang et al., 2014), we have 
observed that OLs express both GAD65/67 and MAOB. Additionally, we have detected GABA 
itself in OPCs, NG2+ cells and OLs at different stages of maturation by immunostaining and in 
OL culture medium by ELISA (data not shown). These findings suggest that OLs synthesize 
GABA possibly for a proper differentiation and maturation (Serrano-Regal et al., 2019) and 
confirm previous observations by Barres et al (1990), who demonstrated GABA synthesis via 
putrescine in primary OPC cultures. In agreement with that, Bergmann glia and Schwann cells 
have the ability to produce GABA and respond to this neurotransmitter, suggesting a putative 
autocrine/paracrine signaling with additional roles in axon-glia communication (Yoon et al., 
2014; Corell et al., 2015). Determining if OLs are able to release GABA at sufficient 








2. GABA via GABABRs regulates oligodendrocyte differentiation and myelination in 
vitro  
 
Different studies point at GABA as one of the modulators of oligodendroglial cell 
proliferation, differentiation and myelination (Zonouzi et al., 2015; Hamilton et al., 2017). 
Hamilton et al. (2017) suggested that endogenous GABA, via GABAARs, reduces the number of 
oligodendroglial cells and, therefore, negatively modulates myelination in situ in cortical slices. 
In contrast, these authors report that activating or blocking GABABRs has no effect on the 
number of OLs, the later in agreement with our data. In turn, we have observed in DRG-OPC 
cocultures that exogenous GABA and the specific GABABR agonist baclofen regulate 
myelination by increasing MBP levels and myelin sheath segments around axons. These effects 
are likely direct, since GABA stimulation of isolated OPCs accelerates their differentiation into 
mature OLs by promoting an increase in MBP levels in the periphery of the cells, suggesting 
that these molecules are promoting local translation of MBP in distal areas. In addition, 
chronic treatment with baclofen in cultured OLs enhances the production of the myelin 
proteins MAG and MBP, an event prevented by the GABABR specific antagonist CGP55845. On 
the other hand, selective activation of GABAARs does not change the levels of these myelin 
proteins (Serrano-Regal et al., 2019). Thus, our results indicate that potentiation of MBP 
expression and OL differentiation by GABA is mainly mediated by GABABRs, as observed in 
Schwann cells (Procacci et al., 2013; Corell et al., 2015) and in a similar way as NMDA receptor-
mediated OPC differentiation (Li et al., 2013; Lundgaard et al., 2013).  
 
To elucidate the underlying mechanisms of the GABABR-induced OL differentiation, we 
investigated whether this effect is due to an increase in OPC proliferation. We observed that 
neither GABA nor baclofen have an impact on OPC proliferation in vitro. This result is at odds 
with the idea that GABA decreases OPC proliferation as suggested by Hamilton et al. (2017). 
However, it is important to note that dissociated in vitro cultures might behave differently 
than a more integral preparation such as organotypic slices, where different type of cells 






3. Baclofen-induced MBP upregulation in vitro requires the participation of Src-
family kinases and the phosphorylation of CREB 
 
We then explored the downstream molecular mechanisms underlying GABABR-
induced OL differentiation. On one hand, we tested whether GABABR activation initiated Fyn 
kinase signaling, a known integrator of neuronal signals that regulates the morphological 
differentiation of OLs, the recruitment of cytoskeleton components and the MBP local 
translation (White and Krämer-Albers, 2014). Indeed, GABABR stimulation mediates 
chemotaxis and cytoskeletal rearrangement, which is dependent on signaling via PI3-K/Akt/Src 
kinases, and the modulation of this pathway may be potentially used to regulate cellular 
responses to injury and disease (Barati et al., 2015). Our data show that chronic treatment 
with baclofen in rat OPC cultures induces Src-phosphorylation. Additionally, GABAB-R-induced 
OL differentiation is blocked by the Src-family kinases inhibitor PP2, suggesting that Src-family 
acts downstream of GABABR to favor OL differentiation and local translation of MBP in OL 
distal processes (Serrano-Regal et al., 2019). Similarly, activation of Src and phospho-FAK 
kinases promotes Schwann cell development and maturation, though these events lie under 
control of GABAAR-dependent mechanisms (Melfi et al., 2017). 
 
On the other hand, CREB is a mediator in the stimulation of MBP expression and plays 
an important role in OL differentiation and myelination (Afshari et al., 2001). Its 
phosphorylation is regulated by several extracellular and intracellular signals involving the 
participation of multiple protein kinases (Mao et al., 2007). Moreover, stimulation of GABABRs 
with baclofen mediates CREB upregulation in cultured mouse cerebellar granule neurons 
(Zhang et al., 2015). Thereby, we then analyzed CREB phosphorylation and we found that 
treatment with baclofen induces rapid CREB phosphorylation, an effect that is prevented in the 
presence of the GABABR antagonist CGP55845. These results corroborates that baclofen-
induced MBP upregulation involves CREB activation.  
 
4. GABAergic signaling modulates oligodendrocyte differentiation in organotypic 
cultures  
 
GABA is an inhibitory neurotransmitter, however in the immature brain plays an 




and synapse formation (Ben-Ari, 2002). The relationship between neuronal activity and 
oligodendroglial cell function impacts on myelin and axon dynamics and the signals involved in 
this communication are crucial for circuit formation and maturation. In addition, this is a key 
event for network functioning (Habermacher et al., 2019), as depletion of OLs at postnatal day 
1 affects the establishment of cerebellar circuitries in mice (Doretto et al., 2011). Myelination 
has a prominent peak during postnatal development, and considering that OPCs receive 
glutamatergic and GABAergic synaptic inputs (Bergles et al., 2000; Lin and Bergles, 2004; 
Karadottir et al., 2008; Fannon et al., 2015; Zonouzi et al., 2015), signaling through GABARs 
might be important for OPC development and differentiation as well as  for OLs to initiate 
myelination of axons. This has been reported for GABAARs (Zonouzi et al., 2015; Hamilton et 
al., 2017), but participation of GABABRs in these events is not yet completely known. To 
answer this question, we analyzed the impact of the GABARs-mediated signaling on OL 
differentiation and myelination during in vitro development using cerebellar organotypic 
cultures. We observed that GABABR stimulation with baclofen promotes an increase in the 
myelin-related proteins MAG, CNPase and MBP that is not observed neither when GABAARs 
are stimulated with muscimol nor when both GABAARs and GABABRs are activated with 
exogenous GABA. In the latter, the non-detection of the same effect of that promoted by 
baclofen may be due to a dual activation of GABAA and GABABRs by GABA, promoting 
activation of several signaling cascades that could mediate opposing actions and mask the 
upregulation of myelin proteins observed with baclofen alone. Surprisingly, we found an 
increase in CNPase levels when slices were treated with the GABABR antagonist CGP55845, 
which seems to be contradictory to what is mentioned before. However, GABABRs in 
organotypic slicesare present in oligodendroglia and other cells and CGP55845 is not cell-
specific. This fact may have a different impact on oligodendroglial cells, in which CNPase is 
crucial during development for process formation and branching (Raasakka and Kursula, 
2014), but the exact mechanism has not been evaluated yet.  
 
On the other hand, in optic nerve organotypic explants from PLP-DsRed, we observed 
an increase in DsRed fluorescent signal in nerves treated with baclofen versus controls. 
Altogether, these results suggest that specific stimulation of GABABRs with baclofen also 
upregulates the expression of the mature oligodendrocyte marker PLP in organotypic cultures. 
 
Using a similar approach as in dissociated cultures, we observed in cerebellar 




with gabazine induce changes in PDGFRα levels, indicating that the OPC population does not 
change under these conditions. In addition, EdU labeling did not reveal changes in OL 
proliferation neither with GABA nor with the specific agonists for each GABAR. This is in 
contrast to the study from Hamilton et al. (2017), who proposed that endogenous GABA via 
GABAARs reduces the number of total oligodendroglial cells. However, the fact that they used 
cortical slices could underlie this apparent contradiction, since cells from different CNS areas 
may behave and interact in a different manner regarding GABA signaling. In this sense, OPCs 
are functionally heterogeneous among brain regions and different ages because they have 
different expression of ion channels (Spitzer et al., 2019). Apart from that, we observed a 
reduction in the number of mature OLs and total oligodendroglial cells in the cerebellar slices 
treated with muscimol, which indicates that GABAAR activation at this time point may be 
decreasing OPC proliferation and their subsequent differentiation into mature OLs. This late 
observation is in accordance with the proposal from Hamilton et al. In agreement with this, 
Zonouzi et al. (2015) also suggest that GABAergic signaling via GABAARs regulates OPC 
proliferation in vivo in a mouse model of diffuse white matter injury. 
 
5. GABAergic signaling modulates LPC-induced myelin damage and restores MAG 
levels in cerebellar organotypic cultures 
 
As cerebellar organotypic cultures constitute an excellent model to study 
remyelination (Tan et al., 2018), we next performed LPC-experimental demyelination in 
cerebellar slices in order to analyze the impact of the GABAergic drugs in this issue. We carried 
out two different experimental designs. First, we analyzed the effect of the GABAergic 
modulators after the demyelinating insult, specifically focusing on remyelination. Our results 
show that in the presence of baclofen, MAG protein levels recover after LPC-induced 
demyelination, which points at baclofen as a possible modulator of remyelination However, 
we did not find a restoration of MBP with any of the treatments. Moreover, we analyzed 
association of MBP and neurofilament, but we did not find any significant effect either. Thus, 
although we did not observe a recovery of MBP levels with these approaches, we propose to 
further investigate this question modifying times and drug concentrations and  analyzing in 
detail other parameters, as the nodes of Ranvier and the state of other proteins present in 





In the second experimental design, we applied the drugs together with LPC, and we 
observed that activation of GABARs with GABA, baclofen or muscimol ameliorates LPC-induced 
decrease of MAG and MBP myelin proteins. On the other hand, in cerebellar slices from 
transgenic PLP-DsRed mice, no loss of PLP induced by LPC occurred in the presence of 
baclofen, gabazine and GABA+gabazine. The latter suggests that activation of GABABR or block 
of GABAAR modulates myelin restoration after a demyelinating insult. Blocking GABAARs with 
gabazine could provoke that endogenous GABA, present in cerebellar organotypic 
preparations, acts preferably via GABABRs, reinforcing its role in OL differentiation and 
myelination. Hamilton and colleagues (2017) indicated a similar possibility to justify the effect 
of endogenous GABA release on oligodendrocyte development in cerebral cortical slices, 
where blocking GABAARs with gabazine increased the number of oligodendrocyte lineage cells. 
They suggested that GABA could be release from OPCs or astrocytes, as both synthesize GABA 
from putrescine using MAOB (Barres et al., 1990; Yoon et al., 2014).  In addition, they 
postulated that gabazine could also act on neurons, increasing spiking frequency and 
promoting the release of substances that affect oligodendroglial population. Finally, they 
concluded that a combination of both events might explain their results, and point that the 
difference in behavior from the cerebellar OPCs studied by Zonouzi et al. (2015) could reflect 
the difference in the brain area studied (Hamilton et al., 2017), an interpretation that could be 
extended to the results of our work.   
 
6. Baclofen promotes in vivo OL differentiation and accelerates postnatal 
myelination in rats  
 
We performed in vivo studies in rats to further analyze the effect of GABABR activation 
in OL differentiation and myelination during development. Immunohistochemical studies at 
P12 revealed an increase in OL differentiation in the corpus callosum of baclofen-treated rats 
compared to controls, which is in accordance with our results in vitro and supports the role of 
GABABR as a key regulator of OL differentiation. On the other hand, total number of 
oligodendroglial cells remained unchanged after baclofen treatment. Despite Luyt et al. (2017) 
described an increase in OPC proliferation in vitro after baclofen exposure, our results in vivo 
are in agreement with those obtained in vitro (Serrano-Regal et al., 2019) and with the 
observations by Corell et al. (2015), who reported that GABABR activation with baclofen does 





In contrast to the results above, we did not observe an increase in the number of 
mature OLs in the presence of baclofen in more advanced stages of development (P34-P42). 
Considering that mature OLs mostly arise during the first postnatal weeks (Habermacher et al., 
2019), our data indicates that baclofen appears to be more effective in sizing the 
oligodendrocyte population. Thus, the lack of changes in the number of mature OLs at 
advanced stages of development may be due to a strong reduction in the differentiation rate 
at these ages. In contrast, we found an enhancement in MBP fluorescence intensity between 
P34-P42, both in the corpus callosum and the cingulate cortex. This latter result reflects that 
myelination is potentiated by GABABR activation since it modulates the peak of myelination, 
which in rats takes place around P20 (Downes and Mullis, 2014). Altogether, these results 
suggest that GABA signaling specifically through GABABRs accelerates OL differentiation and 
MBP production during development. Improving myelination during development is crucial to 
deal with neurological and psychological disorders that appear caused by white matter 
disturbances (Travis et al., 2019). 
 
Interestingly, we found a side effect after in vivo administration of baclofen. Animals 
treated with this drug exhibited a slower gain of weight body during development (data not 
shown) which may be due to the systemic effects of GABA signaling as it is known that GABAR 
expression is not restricted to the nervous system. Purwana et al. (2014) demonstrated that 
GABA modulates glucose homeostasis. In this study, GABA treatment increases β-cell mass in a 
mouse model of diabetes transplanted with human islets. This fact was associated with 
increased insulin circulating levels and reduced blood glucose levels, and was attributed to 
both GABAA and GABABRs involving the activation of the PI3K-Akt signaling pathway and the 
stimulation of CREB. Thus, this reduction in the body weight observed in our experiment may 
be explained by the modulation of glucose homeostasis exerted by GABARs. Another possible 
explanation may be that myelination is a costly process in terms of energy, as enough lipids 
and proteins are produced in order to wrap many membranes around axons. This energetic 
investment may require more food intake or burning body fat (Harris and Attwell, 2012). 
Considering that, baclofen-treated animals could have an unbalance in their metabolism, 
burning more calories than what they intake. 
 
As myelin allows fast propagation of nerve impulses (Baumann and Pham-Dinh, 2001) 
and the corpus callosum is the biggest white matter tract in the brain, we checked the 




that end, we recorded compound action potentials (CAPs) of the corpus callosum fibers in 
order to determine if treatment with baclofen modified its conduction velocity. The corpus 
callosum is widely used to study white matter function under physiological and pathological 
conditions. It contains both myelinated and unmyelinated axons and constitutes a great 
structure to characterize the electrophysiological pattern of white matter. Two types of phase 
peaks are present in CAP traces. The early peak (N1) represents the conduction of myelinated 
axons, whereas the late peak (N2) represents unmyelinated fibers. The heterogeneity of the 
CAPs responses between the rostral and the caudal part of the corpus callosum is due to the 
different proportion of myelinated and non-myelinated axons (Mu et al., 2019). This argument 
matches with the fact that in our study we have observed the appearance of a third peak in 
CAPs recordings in the first place (N0). Thus, we can classify the fibers in myelinated (N0), 
partially myelinated (N1) and unmyelinated (N2). Our data show that GABABR activation with 
baclofen decreases the latency of myelinated fibers (N0) meaning that its conduction velocity 
is increased, whereas the conduction of N1 and N2 fibers remain unchanged. Thus, although 
further analysis including electron microscopy may help to confirm this hypothesis, we 
hypothesize that the increase in the conduction velocity produced by baclofen is associated 
with a higher myelination ratio. This result is consistent with the effects of baclofen 
modulating OL differentiation and myelination, and reinforces the role of GABABR activation in 
myelination in vivo. 
 
7. GABABR activation promotes OPC differentiation without modifying proliferation 
in vivo after LPC-induced demyelination  
 
Given that primary demyelination is the main pathological hallmark of MS and pre-
existing OLs do not contribute to myelin restoration (Franklin and ffrench-Constant, 2017), it is 
necessary to develop therapies that stimulate OPC differentiation into mature OLs and 
promote remyelination (Lassmann and Bradl, 2017). With this goal in mind, we decided to 
assess the potential role of baclofen in promoting OPC differentiation after LPC-induced 
demyelination in vivo in the mouse spinal cord. This model drives toxic demyelination without 
the complication of an autoimmune response (Franklin and ffrench-Constant, 2017). LPC 
injection induces focal plaques of demyelination due to its detergent action against the myelin 
sheath (Jeffery and Blakemore, 1995) and it is a useful experimental setting to study OL 
differentiation (Azim and Butt, 2011). Thus, after treating LPC-injected mice with baclofen, we 




of OPC differentiation. Our results show that whereas the number of OPCs and 
oligodendroglial cells remain unchanged, treatment with baclofen increases OPC 
differentiation into mature OLs. As pre-existing OLs do not contribute to remyelination 
following toxin-induced demyelination (Crawford et al., 2016), these mature OLs derived from 
OPCs withinthe lesion. This result indicates that at that stage baclofen is able to induce OPC 
differentiation but not OPC recruitment whose peak takes place at 7 dpl. Therefore, although 
the specific contribution of baclofen to remyelination needs to be evaluated later in time -at 
the peak phase of remyelination (21 dpl)- this result shows the potential role of baclofen in 
promoting OPC differentiation and the initial stages of remyelination in a pathological context. 
This observation highlights the relevance of the GABAergic metabotropic signaling in 
modulating OL differentiation and myelination under pathological conditions, as described 
earlier for GABAARs (Zonouzi et al., 2015; Kalakh and Mouihate, 2019).  
 
Finally, microglial cells are key to the inflammatory response that occurs in the 
damaged area after LPC-induced demyelination (Bieber et al., 2003). Thus, we also evaluated 
the efficacy of baclofen in modulating the inflammatory response triggered by these glial cells, 
so we analyzed changes in microglial cell number. At 12 dpl, treatment with baclofen did not 
induce changes in microglia, indicating that the treatment may be out of the time window in 
which baclofen exerts its effects. Nonetheless, we need analyze additional parameters to 
further assess the potential of baclofen in modulating microglial inflammatory response, as 
changes in cellular morphology, release of pro and anti-inflammatory molecules or phagocytic 
capacity of these cells to engulf myelin debris. 
 
Overall, the present study introduces an important role for the GABAergic system via 
GABABRs in oligodendroglial cell differentiation and myelination. In particular, it will be 
relevant to study the role of GABA in demyelinating diseases, such as MS, in which reduced 
GABA levels are associated with cognitive impairment and physical disability (Cawley et al., 
2015; Cao et al., 2018). Since baclofen is already used as a treatment for spasticity in MS 
(Stevenson 2014; Ertzgaard et al., 2017), elucidating its exact role in OL differentiation and 
myelination may reinforce its clinical use. In addition, understanding their mechanisms of 
action may be relevant for the development of new therapies that promote remyelination 
under pathological conditions. 
 
CONCLUSIONS 
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